



HHS Public Access

Author manuscript

J Med Chem. Author manuscript; available in PMC 2016 December 14.

Published in final edited form as:

J Med Chem. 2016 March 10; 59(5): 1899–1913. doi:10.1021/acs.jmedchem.5b01464.

Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 3CL Protease

Vishnu C. Damalanka[†], Yunjeong Kim[‡], Kevin R. Alliston[†], Pathum M. Weerawarna[†], Anushka C. Galasiti Kankanamalage[†], Gerald H. Lushington^{||}, Nurjahan Mehzabeen[§], Kevin P. Battaile[⊥], Scott Lovell[§], Kyeong-Ok Chang^{*‡}, and William C. Groutas^{*†}

[†]Department of Chemistry, Wichita State University, Wichita, Kansas 67260, United States

[‡]Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas 66506, United States

[§]Protein Structure Laboratory, The University of Kansas, Lawrence, Kansas 66047, United States

^{||}LiS Consulting, Lawrence, Kansas 66046, United States

[⊥]IMCA-CAT, Hauptman-Woodward Medical Research Institute, APS Argonne National Laboratory, Argonne, Illinois 60439, United States

Abstract

Human noroviruses are the primary causative agents of acute gastroenteritis and a pressing public health burden worldwide. There are currently no vaccines or small molecule therapeutics available for the treatment or prophylaxis of norovirus infections. Norovirus 3CL protease plays a vital role in viral replication by generating structural and nonstructural proteins via the cleavage of the viral polyprotein. Thus, molecules that inhibit the viral protease may have potential therapeutic value. We describe herein the structure-based design, synthesis, and in vitro and cell-based evaluation of the first class of oxadiazole-based, permeable macrocyclic inhibitors of norovirus 3CL protease.

Graphical abstract

*Corresponding Authors: K.-O.C.: phone, 785-532 3849; fax, 785-532 4039; kchang@vet.ksu.edu. W.C.G.: phone, 316-978 7374; fax, 316-978 3431; bill.groutas@wichita.edu.


Accession Codes

Coordinates and structure factors were deposited to the wwPDB with accession codes 5DGJ (NV 3CLpro:21) and 5DG6 (NV 3CLpro:22).

The authors declare no competing financial interest.

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmed-chem.5b01464.
Molecular formula strings (CSV)



INTRODUCTION

Human noroviruses belong to the genus *Norovirus* in the family Caliciviridae.¹ They are the primary cause of sporadic and epidemic nonbacterial gastroenteritis outbreaks worldwide.^{2–5} Norovirus infection is associated with high morbidity among the elderly and young, as well as immunocompromised patients.⁶ The mortality rate among children in developing countries is estimated to exceed 200 000 annually.⁷ Of the six norovirus genogroups (GI–VI), GI and GII are associated with human infections, with the GII.4 cluster accounting for 70–80% of norovirus outbreaks worldwide.⁸ Devising prophylactic and/or therapeutic interventions for norovirus infection presents a challenge due to the high transmissibility, genetic diversity, environmental stability, and prolonged virus shedding displayed by noroviruses.^{9,10} Furthermore, human noroviruses do not robustly grow in cell culture and only low levels of human norovirus are reported to grow in human B cells.¹¹ Lastly, there is currently no optimal animal model of the disease; consequently, many aspects of norovirus biology and pathogenesis are poorly understood.¹²

The norovirus RNA genome (7.4–7.7 kb) is a positive-sense single stranded genome comprising three open reading frames (ORF1–3) of which ORF1 encodes a 200 kDa polyprotein that is proteolytically cleaved to generate at least six nonstructural proteins: p48, RNA helicase/NTPase, p22, VPg, 3C-like protease (3CLpro), and RNA-dependent RNA polymerase (RdRp).^{1,13} ORF2 and ORF3 encode the norovirus capsid (VP2) and a small basic protein (VP1), respectively. Processing of the polyprotein is effected by the norovirus 3CLpro, a cysteine protease having a chymotrypsin-like fold, an extended binding cleft, and a Cys-His-Glu catalytic triad.^{14–16} The preferred substrate recognition sequence for 3CLpro is –F/Y-X-L-Q-G/A– corresponding to –P₄-P₃-P₂-P₁-P₁'–,¹⁷ where the P₁ Gln residue determines the primary substrate specificity of the enzyme and X is H, Q, or E.^{18–20} The S₃ subsite displays a degree of plasticity and, therefore, can accommodate a P₃ Gln, His, or Glu. Because processing of the polyprotein by 3CLpro is essential for viral replication, inhibition of 3CLpro is envisaged to be a fruitful avenue of investigation for the discovery of

norovirus-specific antivirals, an approach that has been successfully used in the discovery of therapeutics for other viral diseases.^{21,22} We have recently described an array of inhibitors of 3CLpro,^{23–27} including the demonstration of in vivo efficacy by a dipeptidyl inhibitor using a murine norovirus model.²⁸ We report herein the results of structural, biochemical, and antiviral studies of a novel series of oxadiazole-based cell permeable macrocyclic inhibitors (I) (Figure 1) of norovirus 3CLpro.

RESULTS AND DISCUSSION

Inhibitor Design Rationale

There are several disadvantages associated with peptide-derived drugs, including high conformational flexibility, susceptibility to proteolytic degradation, poor membrane permeability, and low oral bioavailability.^{29,30} These shortcomings are frequently mitigated through depeptitization. An effective way of depeptitizing a linear peptide is through macrocyclization.^{31–34} The preorganization and structural rigidity that characterize macrocyclic inhibitors frequently enhance pharmacological activity by reducing the entropic penalty associated with binding and, furthermore, increase proteolytic stability.³⁴ The effect of macrocyclization on cellular permeability and oral bioavailability is less predictable; however, these parameters are expected to be augmented when a macrocycle can engage in intramolecular hydrogen bonding.^{35,36} On the basis of these considerations, we hypothesized that tethering of the P₁ Gln residue, the preferred primary substrate specificity residue of norovirus 3CLpro, with the P₃ residue side chain in an appropriate linear peptide using a 1,3,4-oxadiazole linker would yield a macrocyclic scaffold (I) (Figure 1) potentially capable of participating in intramolecular hydrogen bonding via the ring oxygen or nitrogen atoms, depending on the orientation assumed by the heterocyclic ring. Additional design considerations included ensuring that the ring size of the macrocycle would be optimal in terms of allowing the macrocycle to assume a β -strand conformation, a structural motif recognized by proteases.^{37,38} This is of paramount importance, since a β -strand conformation would allow proper docking/positioning of the inhibitor to the active site which, in turn, would orient correctly the side chains of the P₁ and P₂ residues, thereby maximizing hydrogen bonding and hydrophobic binding interactions. Lastly, the length of the linker and the position of the heterocyclic ring were also anticipated to influence permeability and potency by impacting the conformation of the macrocycle (vide infra).

Chemistry

A convergent approach was used in the synthesis of inhibitors **15–22** (Table 1). Thus, fragments **4a–f** and **6** were first assembled as illustrated in Scheme 1. Fragments **4a–f** were synthesized by coupling an appropriate Z-protected carboxylic acid with *tert*-butyl carbazate using EDCI to yield the Boc-protected hydrazides **1a–e**. The Boc protective group was removed via treatment with dry HCl/dioxane, and the resulting hydrazine was coupled to (L)-Boc-glutamic acid α -methyl ester using EDCI/HOBt/DIEA/DMF to yield hydrazides **2a–f**. Reaction with *p*-toluenesulfonyl chloride/DIEA in dry CH₃CN yielded 1,3,4-oxadiazole derivatives³⁹ **3a–f** which were hydrolyzed with LiOH in aqueous THF to yield the corresponding acids **4a–f**. Fragment **6** was readily prepared via the esterification of commercially available (L)-Boc-Glu-(OBzl)-OH with CH₃I/NaHCO₃/DMF, followed by

removal of the Boc-group to yield **5**, which was then coupled to (L)-Boc-Leu using EDCI/HOBt/DIEA/DMF to form fragment **6**. Coupling of fragments **4a–f** and **6** generated leucine-substituted intermediates **7a–c** and **7e** (Scheme 2). The corresponding cyclohexylalanine-substituted compounds **7d** and **7f–h** were prepared by coupling compounds **4a–f** to (L)-cyclohexylalanine methyl ester to give esters **13a–d** which were hydrolyzed to the corresponding carboxylic acids **14a–d** (Scheme 3). Coupling of the acids with (L)-Glu(OBzl) methyl ester yielded compounds **7d** and **7f–h**. Treatment of compounds **7a–h** with H₂/Pd–C furnished acyclic precursors **8a–h**. Subsequent macrolactamization⁴⁰ yielded compounds **9a–h** which, upon reduction with lithium borohydride, generated the corresponding alcohols **10a–h**. Oxidation to aldehydes **15–22** was accomplished using Dess–Martin periodinane, and the synthesized compounds are listed in Table 1.

Biochemical Studies

The inhibitory activity of compounds **15–22** toward NV 3CLpro, as well as their antinorovirus activity in the NV replicon harboring cells established in Huh-7 cells, was determined as previously described,^{26,28,41} and the results are tabulated in Table 1. A graphical dose-dependent inhibition of NV RNA replication by compound **21** is shown in Figure 2. The screening results shown in Table 1 indicate that (a) in a comparison of compounds **15**, **16**, and **22** versus compounds **17–21**, it is clearly evident that ring size has a profound impact on inhibitory activity and cellular permeability in this series of compounds; (b) with the exception of compound **22**, the rest of the inhibitors were relatively well-permeable to cells and several inhibitors displayed single digit 50% inhibitory concentration (EC₅₀) values in cell based assays (both NV and murine norovirus-1 (MNV-1)); and (c) in contrast to acyclic dipeptidyl transition state inhibitors where the substitution of a P2 Leu residue by a P2 Cha residue results in significant improvement in both IC₅₀ and EC₅₀ values,²⁸ the presence of Cha at P2 did not markedly change potency (compounds **17** and **18**; compounds **19** and **20**), suggesting that a fruitful strategy for further optimization of potency may necessitate structural modifications in the “cap”. In addition, the EC₅₀ values against NV and MNV-1 in cell culture were well correlated (Table 1), suggesting the potency (and permeability) of each compound was consistent against multiple noroviruses.

X-ray Crystallographic Studies

In order to establish the precise mechanism of action of inhibitor (I), illuminate the conformation of (I) and the orientation of the linker, as well as obtain structural information that can be used to guide the optimization of pharmacological activity, high resolution X-ray crystal structures of inhibitors **21** and **22** with NV 3CLpro were determined. Examination of the active site revealed the presence of prominent electron density in subunit A consistent with inhibitors **21** and **22** covalently bound to Cys 139 and the cyclohexyl alanine side chain nestled into the hydrophobic S₂ subsite¹⁷ (Figure 3). However, for inhibitor **21**, the majority of the macrocycle was disordered and could not be modeled. This disorder was consistently observed from approximately 10 X-ray diffraction data sets obtained for this complex. A surface representation of NV 3CLpro, colored by residue type, with inhibitor **22** is shown in Figure 4.

The hydrogen-bonding interactions between NV 3CLpro and inhibitors **21** and **22** are shown in Figure 5 and include multiple hydrogen bonds between Ala160, Gln 110, and Ala158 and the inhibitor backbone which serve to correctly position the inhibitor in the active site cleft. Critical hydrogen bonds involving the P1 Gln side chain and the His157 and Thr134 residues are also clearly evident for inhibitor **22**. However, hydrogen bonding to Thr134 was not observed for the complex with inhibitor **21** due to disorder of the residues between Leu132 and Gly137. These binding interactions, as well as the flexible backbone of the T123-G133 loop, are postulated to play a critical role in enzyme recognition.⁴² The lack of cellular permeability of inhibitor **22** is supported by the absence of any intramolecular hydrogen bonds with the oxadiazole ring; however, permeability involves the interplay of many factors besides intramolecular hydrogen bonding. Notably, interactions between inhibitor **21** and Thr134 were not observed, since the loop of NV 3CLpro spanning Gly133-Pro136 was consistently disordered. Thus, it seems that the macrocycle ring size may play a role in forming optimal hydrogen bond interactions with NV 3CLpro. Surprisingly, decreasing the macrocycle ring from 21 atoms (inhibitor **22**) to 20 atoms (inhibitor **21**) results in more disorder of the inhibitor and nearby residues of NV 3CLpro. In order to gain insight and understanding into the structural determinants that impact potency and cellular permeability, herculean efforts were expended in obtaining high resolution X-ray crystal structures of permeable inhibitors **18–20**, albeit without success. Although crystals were obtained for NV 3CLpro cocrystallized with inhibitors **18–20**, these samples only yielded weak X-ray diffraction properties even after optimization of the crystallization conditions. Finally, the crystallographic data indicate that the oxadiazole-based macrocyclic inhibitors weaken all H-bonding prospects for this pharmacophore element.

In an effort to correlate the crystal structures with the data provided in Table 1, the structures of NV 3CLpro were superimposed using secondary structure matching with GESAMT.⁴³ Not surprising, the overall structures of the NV 3CLpro were very similar to an rmsd of 0.54 Å between C α atoms (158 residues). In order to conduct a more direct analysis of the inhibitors, the disordered portion of the macrocycle for inhibitor **21** was modeled in an idealized position and compared with inhibitor **22** (Figure 6). Notably, the shorter ring size of inhibitor **21** appears to move the inhibitor slightly away from the loop containing Thr134 which precludes formation of a hydrogen bond and disorder of residues Gly133-Pro136 in the nearby loop. However, inhibitor **22** is able to stabilize this loop region by formation of a hydrogen bond with Thr134 due to the larger ring size. This perhaps explains the observed difference in the IC₅₀ values (Table 1), as inhibitor **22** is able to form an extra hydrogen bond relative to the other inhibitors. Further shortening of the macrocycle ring size (inhibitors **15–20**) would likely move the inhibitor further away from Thr134 and prevent formation of hydrogen bonds with the loop and result in disorder of these residues. This may also explain why the crystals obtained with inhibitors **18–20** produced poor diffraction, as the dynamic conformations of the nearby loop could potentially prevent formation of well-ordered crystals. Conversely, the shorter macrocycle ring size appears to be more conducive to permeability, although binding to the NV 3CLpro target is slightly weakened.

CONCLUSIONS

There is currently a dire need for the development of norovirus-specific therapeutics and prophylactics for the management of norovirus infections. The studies described herein disclose the structure-based design of the first series of oxadiazole-based permeable macrocyclic inhibitors of norovirus 3CL protease. Insights gained from these studies have laid a solid foundation for conducting further preclinical studies focused on the optimization of potency and pharmacokinetics.

EXPERIMENTAL SECTION

General

Reagents and dry solvents were purchased from various chemical suppliers (Aldrich, Acros Organics, Chem-Impex, TCI America, Oakwood Chemicals, Bachem, and Fisher) and were used as obtained. Silica gel (230–450 mesh) used for flash chromatography was purchased from Sorbent Technologies (Atlanta, GA). Thin layer chromatography was performed using Analtech silica gel plates. The ^1H spectra were recorded in CDCl_3 or $\text{DMSO}-d_6$ on a Varian XL-400 NMR spectrometer. High resolution mass spectrometry (HRMS) experiments were performed at the University of Kansas Mass Spectrometry lab using an LCT Premier mass spectrometer (Waters, Milford, MA) equipped with a time-of-flight mass analyzer and an electrospray ion source. Visualization was accomplished using UV light and/or iodine. Reverse phase HPLC was utilized to determine the purity of the final compounds (>95% purity).

Peptide Coupling Reactions. Synthesis of Compounds 1a–e. General Procedure

To a stirred solution of N-protected amino acid derivative (112 mmol) in dry CH_2Cl_2 (400 mL) was added EDCI (135 mmol), and the reaction mixture was stirred for 30 min at ambient temperature. *t*-Boc hydrazide (196 mmol) was added, and the reaction mixture was stirred for 18 h at room temperature. The solution was washed with 5% aqueous HCl (2×100 mL), saturated NaHCO_3 (2×100 mL), and brine (100 mL). The organic phase was dried over anhydrous Na_2SO_4 , filtered, and concentrated to yield the desired compounds.

***tert*-Butyl 2-(((Benzyloxy)carbonyl)glycyl)hydrazine-1-carboxylate (1a)**

Yield (80%), mp 49–52 °C. ^1H NMR (400 MHz, CDCl_3) δ 1.37–1.49 (s, 9 H), 3.89 (br s, 2 H), 5.03–5.14 (s, 2 H), 7.25–7.37 (m, 5 H), 7.39–7.48 (m, 2 H). HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{21}\text{N}_3\text{O}_5\text{Na}$, $[\text{M} + \text{Na}]^+$: 346.1379. Found: 346.1381.

***tert*-Butyl 2-(3-(((Benzyloxy)carbonyl)amino)propanoyl)-hydrazine-1-carboxylate (1b)**

Yield (78%), mp 139–141 °C. ^1H NMR (400 MHz, CDCl_3): δ 1.41–1.53 (s, 9 H), 2.41–2.47 (m, 2 H), 3.45–3.55 (m, 2 H), 5.05–5.12 (s, 2 H), 6.50–6.58 (s, 1 H), 7.25–7.38 (m, 5 H), 7.63 (br s, 1 H). HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{23}\text{N}_3\text{O}_5\text{Na}$, $[\text{M} + \text{Na}]^+$: 360.1535. Found: 360.1533.

tert-Butyl 2-(4-(((Benzyloxy)carbonyl)amino)butanoyl)-hydrazine-1-carboxylate (1c)

Oil, yield (80%). ¹H NMR (400 MHz, CDCl₃): δ 1.45 (s, 9 H), 1.80–1.92 (m, 5 H), 2.26 (t, *J* = 7.02 Hz, 3 H), 3.19–3.31 (m, 4 H), 5.05–5.17 (s, 2 H), 5.28–5.39 (m, 1 H), 6.70 (br s, 1 H), 7.26–7.39 (m, 5 H), 8.24–8.35 (m, 1 H). HRMS (ESI) calcd for C₁₇H₂₆N₃O₅ [M + H]⁺: 352.1872. Found: 352.1874.

tert-Butyl 2-(5-(((Benzyloxy)carbonyl)amino)pentanoyl)-hydrazine-1-carboxylate (1d)

Oil, yield (83%). ¹H NMR (400 MHz, CDCl₃) δ 1.42–1.47 (s, 9 H), 1.48–1.56 (m, 2 H), 1.59–1.71 (m, 2 H), 2.16–2.27 (m, 2 H), 3.17 (q, *J* = 6.64 Hz, 2 H), 5.07 (s, 2 H), 5.22–5.35 (m, 1 H), 7.26–7.39 (m, 5 H). HRMS (ESI) calcd for C₁₈H₂₇N₃O₅Na, [M + Na]⁺: 388.1848. Found: 388.1845.

tert-Butyl 2-(6-(((Benzyloxy)carbonyl)amino)hexanoyl)-hydrazine-1-carboxylate (1e)

Oil, yield (83%). ¹H NMR (400 MHz, CDCl₃) δ 1.33–1.42 (m, 2 H), 1.45 (s, 9 H), 1.59–1.72 (m, 2 H), 2.17–2.27 (m, 2 H), 2.41–2.53 (m, 2 H), 3.13–3.24 (m, 2 H), 3.36–3.47 (m, 1 H), 5.03–5.15 (m, 2 H), 7.26–7.39 (m, 5 H). HRMS (ESI) calcd for C₁₉H₃₀N₃O₅, [M + H]⁺: 380.2185. Found: 380.2182.

Synthesis of Compounds 2a–f. General Procedure

To a solution of (L)-Boc-Glu-OMe (88.5 mmol) in dry DMF (210 mL) were added EDCI (22.05 g, 115.05 mmol, 1.3 equiv), HOBT (17.73 g, 115.05 mmol, 1.3 equiv), and the mixture was stirred for 30 min at room temperature. In a separate flask, a solution of deprotected compounds **1a–e** (24.22 g, 88.5 mmol) in dry DMF (250 mL) cooled to 0–5 °C was treated with diisopropylethylamine (4.75 g, 354 mmol, 4.0 equiv). After the solution was stirred for 30 min, it was added to the solution above and the reaction mixture was stirred for 16 h while monitoring the reaction by TLC. The solvent was removed in vacuo, and the residue was partitioned between ethyl acetate (500 mL) and 5% aqueous HCl (2 × 150 mL). The layers were separated, and the organic layer was further washed with saturated aqueous NaHCO₃ (2 × 150 mL), followed by saturated NaCl (150 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated to yield the desired compounds.

Methyl N⁴-(2-(((Benzyloxy)carbonyl)amino)acetamido)-N²-(tert-butoxycarbonyl)-L-asparaginate (2a)

Yield (82%), mp 84–87 °C. ¹H NMR (400 MHz, CDCl₃): δ 1.36–1.48 (s, 9 H), 2.75–2.82 (m, 1 H), 2.84–2.88 (m, 1 H), 3.65–3.77 (s, 3 H), 3.90–3.98 (s, 2 H), 4.08–4.15 (m, 1 H), 4.57 (ddd, *J* = 9.52, 5.05, 4.86 Hz, 2 H), 5.05–5.15 (s, 2 H), 5.83 (d, *J* = 8.69 Hz, 1 H), 5.97 (br s, 1 H), 7.26–7.38 (m, 5 H). HRMS (ESI) calcd for C₂₀H₂₉N₄O₈, [M + H]⁺: 453.1985. Found: 453.1983.

Methyl N⁵-(2-(((Benzyloxy)carbonyl)amino)acetamido)-N²-(tert-butoxycarbonyl)-L-glutamate (2b)

Yield (88%), mp 85–88 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.36–1.48 (s, 9 H), 1.87–1.98 (t, 2 H), 2.11–2.23 (m, 2 H), 3.68–3.79 (s, 3 H), 3.96–4.03 (s, 2 H), 4.34–4.46 (m, 1 H), 5.06–

5.18 (s, 1 H), 5.10 (s, 2 H), 5.44–5.57 (m, 1 H), 5.94 (br s, 1 H), 7.26–7.38 (m, 5 H), 9.21 (br s, 1 H). HRMS (ESI) calcd for C₂₁H₃₁N₄O₈, [M + H]⁺: 467.2142. Found: 467.2143.

Methyl N⁵-(3-(((Benzyloxy)carbonyl)amino)propanamido)-N²-(tert-butoxycarbonyl)-L-glutamate (2c)

Yield (90%), mp 98–101 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.35–1.43 (s, 9 H), 1.75–1.87 (m, 2 H), 2.18–2.20 (t, 2H), 2.77–2.90 (m, 2 H), 3.05–3.14 (m, 2 H), 3.59–3.67 (s, 3 H), 4.03 (d, *J* = 7.13 Hz, 1 H), 4.98–5.06 (s, 2 H), 7.29–7.42 (m, 5 H). HRMS (ESI) calcd for C₂₂H₃₃N₄O₈, [M + H]⁺: 481.2298. Found: 481.2306.

Methyl N⁵-(4-(((Benzyloxy)carbonyl)amino)butanamido)-N²-(tert-butoxycarbonyl)-L-glutamate (2d)

Yield (85.2%), mp 105–108 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.20–1.30 (m, 1 H), 1.38–1.48 (m, 6 H), 1.38–1.48 (m, 13 H), 1.59–1.71 (m, 3 H), 1.86 (t, *J* = 6.57 Hz, 2 H), 1.88–1.95 (m, 1 H), 2.27–2.40 (m, 5 H), 3.26–3.31 (m, 1 H), 3.70–3.79 (m, 4 H), 5.09 (s, 2 H), 7.29–7.38 (m, 5 H). HRMS (ESI) calcd for C₂₃H₃₅N₄O₈, [M + H]⁺: 495.2455. Found: 495.2451.

Methyl N⁵-(5-(((Benzyloxy)carbonyl)amino)pentanamido)-N²-(tert-butoxycarbonyl)-L-glutamate (2e)

Yield (83%), mp 116–118 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.39–1.46 (m, 7 H), 1.42 (s, 8 H), 1.48–1.58 (m, 2 H), 1.61–1.73 (m, 2 H), 1.89–2.01 (m, 1 H), 2.14–2.22 (m, 1 H), 2.23–2.31 (m, 2 H), 2.33–2.40 (m, 2 H), 3.12–3.25 (m, 2 H), 3.67–3.77 (m, 2 H), 3.70 (s, 3 H), 4.35 (td, *J* = 8.71, 4.49 Hz, 1 H), 5.07 (s, 2 H), 5.24–5.37 (m, 1 H), 5.47–5.59 (m, 1 H), 7.26–7.37 (m, 5 H), 9.03–9.15 (m, 1 H), 9.28–9.39 (m, 1 H). HRMS (ESI) calcd for C₂₄H₃₇N₄O₈, [M + H]⁺: 509.2611. Found: 509.2615.

Methyl N⁵-(6-(((Benzyloxy)carbonyl)amino)hexanamido)-N²-(tert-butoxycarbonyl)-L-glutamate (2f)

Yield (79%), mp 82–85 °C. ¹H NMR (400 MHz, CDCl₃) δ 1.31–1.39 (m, 2 H), 1.40–1.53 (m, 15 H), 1.59–1.70 (m, 2 H), 1.88–2.00 (m, 1 H), 2.15–2.27 (m, 2 H), 2.30–2.43 (m, 2 H), 3.11–3.23 (m, 2 H), 3.67–3.78 (s, 3 H), 4.28–4.39 (m, 1 H), 5.06–5.18 (m, 2 H), 5.07 (s, 2 H), 5.52 (d, *J* = 8.89 Hz, 1 H), 7.26–7.38 (m, 5 H), 8.96–9.08 (m, 1 H), 9.26–9.37 (m, 1 H). HRMS (ESI) calcd for C₂₅H₃₉N₄O₈, [M + H]⁺: 523.2768. Found: 523.2767.

Synthesis of Oxadiazole Compounds 3a–f. General Procedure

To a solution of compound **2** (11.0 g, 22.89 mmol) in dry acetonitrile (275 mL) were added *p*-toluenesulfonyl chloride (13.09 g, 68.67 mmol, 3.0 equiv), DIEA (5.91 g, 45.78 mmol), and the reaction mixture was stirred for 16 h at room temperature while monitoring the reaction by TLC. The solvent was removed in vacuo, and the residue was partitioned between ethyl acetate (300 mL) and 5% aqueous HCl (2 × 100 mL). The ethyl acetate layer was further washed with saturated aqueous NaHCO₃ (2 × 100 mL), followed by saturated NaCl (100 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and

concentrated. The crude product was purified using flash chromatography to yield the desired oxadiazole derivatives **3a–f**.

Methyl (S)-3-(5-(((Benzyloxy)carbonyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)propanoate (3a)

Oil, yield (70%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.42 (s, 9 H), 3.30–3.42 (m, 1 H), 3.71–3.83 (m, 1 H), 3.75 (s, 3 H), 4.60 (d, $J = 6.05$ Hz, 1 H), 4.69–4.81 (m, 1 H), 5.15 (s, 2 H), 5.46 (t, $J = 6.30$ Hz, 1 H), 5.51–5.57 (m, 1 H), 7.26–7.28 (m, 1 H), 7.29–7.41 (m, 5 H). HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{27}\text{N}_4\text{O}_7$, $[\text{M} + \text{H}]^+$: 435.1880. Found: 435.1877.

Methyl (S)-4-(5-(((Benzyloxy)carbonyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanoate (3b)

Oil, yield (73%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.44 (s, 9 H), 2.06–2.17 (m, 2 H), 2.31–2.43 (m, 2 H), 2.86–2.98 (m, 2 H), 3.75 (s, 3 H), 4.34–4.46 (m, 1 H), 4.59 (d, $J = 6.00$ Hz, 1 H), 5.15 (s, 2 H), 5.39–5.52 (m, 1 H), 7.29–7.40 (m, 5 H). HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{29}\text{N}_4\text{O}_7$, $[\text{M} + \text{H}]^+$: 449.2036. Found: 449.2032.

Methyl (S)-4-(5-(2-(((Benzyloxy)carbonyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanoate (3c)

Oil, yield (75%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 1.43 (s, 9 H), 2.04–2.16 (m, 2 H), 2.86–2.94 (t, 2 H), 2.98–3.10 (t, 2 H), 3.62–3.69 (m, 2 H), 3.73 (s, 3 H), 4.35–4.45 (br s, 1H), 5.17–5.25 (br s, 1 H), 5.67–5.72 (br s, 1 H), 5.07–5.13 (s, 2 H), 7.25–7.38 (m, 5 H). HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{31}\text{N}_4\text{O}_7$, $[\text{M} + \text{H}]^+$: 463.2193. Found: 463.2190.

Methyl (S)-4-(5-(3-(((Benzyloxy)carbonyl)amino)propyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)-butanoate (3d)

Oil, yield (75%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.38–1.49 (s, 9 H), 1.96–2.07 (m, 2 H), 2.08–2.11 (m, 2 H), 2.42 (br s, 1 H), 2.84–2.91 (m, 2 H), 2.96–3.06 (m, 2 H), 3.24–3.36 (m, 2 H), 3.74 (s, 3 H), 4.38–4.45 (m, 1H), 5.09 (s, 2 H), 5.12–5.20 (m, 1 H), 7.29–7.40 (m, 5 H). HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{33}\text{N}_4\text{O}_7$, $[\text{M} + \text{H}]^+$: 477.2349. Found: 477.2346.

Methyl (S)-4-(5-(4-(((Benzyloxy)carbonyl)amino)butyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanoate (3e)

Oil, yield (79%), $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 1.37–1.49 (s, 9 H), 1.54–1.67 (m, 2 H), 1.77–1.89 (m, 2 H), 2.30–2.42 (m, 2 H), 2.80–2.93 (m, 4 H), 3.16–3.28 (m, 2 H), 3.74 (s, 3 H), 4.34–4.46 (m, 1 H), 4.96–5.04 (m, 1 H), 5.09 (s, 2 H), 7.27–7.39 (m, 5 H). HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{35}\text{N}_4\text{O}_7$, $[\text{M} + \text{H}]^+$: 491.2506. Found: 491.2504.

Methyl (S)-4-(5-(5-(((Benzyloxy)carbonyl)amino)pentyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)-butanoate (3f)

Oil, yield (80%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 1.37–1.49 (s, 9 H), 1.50–1.60 (m, 2 H), 1.75–1.87 (m, 2 H), 2.81 (t, $J = 7.52$ Hz, 2 H), 2.87–2.95 (m, 2 H), 3.13–3.25 (m, 2 H), 3.71–3.80 (m, 2 H), 3.74 (s, 3 H), 4.36–4.46 (m, 1 H), 4.83–4.96 (m, 1 H), 5.09 (s, 2 H),

5.18–5.31 (m, 1 H), 7.27–7.39 (m, 5 H). HRMS (ESI) calcd for $C_{25}H_{37}N_4O_7$, $[M + H]^+$: 505.2662. Found: 505.2657.

Synthesis of Acids 4a–f. General Procedure

A solution of ester **3** (20 mmol) in THF (30 mL) was treated with 1 M LiOH in aqueous THF (40 mL). The reaction mixture was stirred for 3 h at room temperature, and the disappearance of the ester was monitored by TLC. Most of the solvent was evaporated off, and the residue was diluted with water (25 mL). The solution was acidified to pH \approx 3 using 5% hydrochloric acid (20 mL), and the aqueous layer was extracted with ethyl acetate (3×100 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to yield the desired compound.

(S)-3-(5-(((Benzyloxy)carbonyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)propanoic Acid (4a)

Yield (95%), mp 78–80 °C. 1H NMR (400 MHz, $CDCl_3$) δ 1.42 (s, 9 H), 3.30–3.42 (m, 1 H), 3.71–3.83 (m, 1 H), 4.60 (d, $J = 6.05$ Hz, 1 H), 4.69–4.81 (m, 1 H), 5.15 (s, 2 H), 5.46 (t, $J = 6.30$ Hz, 1 H), 5.51–5.57 (m, 1 H), 7.26–7.28 (m, 1 H), 7.29–7.41 (m, 5 H). HRMS (ESI) calcd for $C_{19}H_{25}N_4O_7$, $[M + H]^+$: 421.1723. Found: 421.1719.

(S)-4-(5-(((Benzyloxy)carbonyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanoic Acid (4b)

Oil, yield (94%). 1H NMR (400 MHz, $CDCl_3$) δ 1.44 (s, 9 H), 2.06–2.17 (m, 2 H), 2.31–2.43 (m, 2 H), 2.86–2.98 (m, 2 H), 4.34–4.46 (m, 1 H), 4.59 (d, $J = 6.00$ Hz, 1 H), 5.15 (s, 2 H), 5.39–5.52 (m, 1 H), 7.29–7.40 (m, 5 H). HRMS (ESI) calcd for $C_{20}H_{27}N_4O_7$, $[M + H]^+$: 435.1880. Found: 435.1885.

(S)-4-(5-(2-(((Benzyloxy)carbonyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanoic Acid (4c)

Yield (94%), mp 96–98 °C. 1H NMR (400 MHz, $CDCl_3$) δ ppm 1.43 (s, 9 H), 2.04–2.16 (m, 2 H), 2.86–2.94 (t, 2 H), 2.98–3.10 (t, 2 H), 3.62–3.69 (m, 2 H), 4.35–4.45 (br s, 1H), 5.17–5.25 (br. s, 1 H), 5.67–5.72 (br s, 1 H), 5.07–5.13 (s, 2 H), 7.25–7.38 (m, 5 H). HRMS (ESI) calcd for $C_{21}H_{29}N_4O_7$, $[M + H]^+$: 449.2036. Found: 449.2047.

(S)-4-(5-(3-(((Benzyloxy)carbonyl)amino)propyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanoic Acid (4d)

Oil, yield (96%). 1H NMR (400 MHz, $CDCl_3$) δ 1.38–1.49 (s, 9 H), 1.96–2.07 (m, 4 H), 2.08–2.11 (m, 2 H), 2.35–2.41 (m, 1 H), 2.42 (br s, 1 H), 2.84–2.91 (m, 2 H), 2.96–3.06 (m, 2 H), 3.24–3.36 (m, 2 H), 4.38–4.45 (m, 1H), 5.09 (s, 2 H), 5.12–5.20 (m, 1 H), 7.29–7.40 (m, 5 H). HRMS (ESI) calcd for $C_{22}H_{30}N_4O_7Na$, $[M + Na]^+$: 485.2012. Found: 485.2017.

(S)-4-(5-(4-(((Benzyloxy)carbonyl)amino)butyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanoic Acid (4e)

Oil, yield (95%). 1H NMR (400 MHz, $CDCl_3$) δ 1.38–1.50 (s, 9 H), 1.55–1.64 (m, 2 H), 1.75–1.84 (m, 2 H), 2.22 (dd, $J = 7.37$, 6.88 Hz, 2 H), 2.42 (d, $J = 7.13$ Hz, 1 H), 2.79–2.91

(m, 2 H), 2.97 (br s, 1 H), 2.99 (t, $J = 7.79$ Hz, 2 H), 3.18–3.27 (m, 2 H), 5.08 (br s, 2 H), 5.44–5.51 (m, 1 H), 7.26–7.38 (m, 5 H). HRMS (ESI) calcd for $C_{23}H_{33}N_4O_7$, $[M + H]^+$: 477.2349. Found: 477.2340.

(S)-4-(5-(5-(((Benzyloxy)carbonyl)amino)pentyl)-1,3,4-oxa-diazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanoic Acid (4f)

Oil, yield (95%). 1H NMR (400 MHz, $CDCl_3$) δ 1.37–1.49 (s, 9 H), 1.50–1.60 (m, 2 H), 1.75–1.87 (m, 2 H), 2.81 (t, $J = 7.52$ Hz, 2 H), 2.87–2.95 (m, 2 H), 3.13–3.25 (m, 2 H), 3.71–3.80 (m, 2 H), 4.36–4.46 (m, 1 H), 4.83–4.96 (m, 1 H), 5.09 (s, 2 H), 5.18–5.31 (m, 1 H), 7.27–7.39 (m, 5 H). HRMS (ESI) calcd for $C_{24}H_{35}N_4O_7$, $[M + H]^+$: 491.2506. Found: 491.2513.

Synthesis of Amino Acid Methyl Esters 5. General Procedure

To a solution of (L)-Boc-Glu(OBzl)-OH (16.86 g, 50 mmol) in dry DMF (100 mL) was added $NaHCO_3$ (25.2 g, 300 mmol) followed by methyl iodide (14.2 g, 100 mmol). The reaction mixture was stirred for 72 h at room temperature. The progress of the reaction was monitored by TLC. The solids were filtered off, and the solvent was removed in vacuo. The residue was partitioned between ethyl acetate (250 mL) and water (2×75 mL). The ethyl acetate layer was washed with saturated NaCl (75 mL) and the organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated to yield an oily product, which was purified by flash chromatography to yield compound **5** as a colorless oil.

5-Benzyl 1-Methyl (tert-Butoxycarbonyl)glutamate (5)

Oil, yield (85%). 1H NMR (400 MHz, $CDCl_3$) δ 1.36–1.49 (s, 9 H), 1.90–2.00 (m, 1 H), 2.12–2.24 (m, 2 H), 2.37–2.48 (m, 2 H), 3.66–3.75 (s, 3 H), 4.25–4.38 (m, 1 H), 5.04–5.16 (m, 1 H), 5.10 (s, 2 H), 7.28–7.40 (m, 5 H).

Synthesis of Compound 6. General Procedure

To a solution of (L)-Boc-Leu-OH (54.87 mmol) in dry DMF (100 mL) were added EDCI (12.83 g, 66.94 mmol, 1.3 equiv), HOBt (10.27 g, 66.94 mmol, 1.3 equiv), and the reaction mixture was stirred for 30 min at room temperature. In a separate flask, a solution of deprotected compound **5** (15.8 g, 54.87 mmol) in dry DMF (100 mL) cooled to 0–5 °C was treated with diisopropylethylamine (DIEA) (28.36 g, 219.48 mmol, 4.0 equiv), stirred for 30 min, and then added to the above reaction mixture. The solution was stirred for 16 h while monitoring the reaction by TLC. The solvent was removed and the residue was partitioned between ethyl acetate (300 mL) and 5% aqueous HCl (2×120 mL). The ethyl acetate layer was further washed with aqueous $NaHCO_3$ (2×120 mL), followed by saturated NaCl (120 mL). The organic layer was dried over anhydrous Na_2SO_4 , filtered, and concentrated to yield a yellow oil which was purified by flash chromatography to yield an oily product which was deblocked with 4 M HCl in dioxane to yield compound **6**.

Synthesis of Compounds 7a–h. General Procedure

To a solution of compound **4** (10.0 g, 22.29 mmol) in dry DMF (100 mL) was added EDCI (5.55 g, 28.98 mmol, 1.3 equiv), and the mixture was stirred for 30 min at room temperature.

In a separate flask, a solution of deprotected compound **6** (7.6 g, 22.29 mmol) in dry DMF (100 mL) cooled to 0–5 °C was treated with diisopropylethylamine (DIEA) (11.52 g, 89.16 mmol, 4.0 equiv), stirred for 30 min, and then added to the reaction mixture above. The solution was stirred for 16 h while monitoring the reaction by TLC, and the solvent was removed in vacuo. The residue was partitioned between (400 mL) and 5% aqueous HCl (2 × 120 mL). The ethyl acetate layer was further washed with saturated aqueous NaHCO₃ (2 × 120 mL), followed by saturated NaCl (120 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude product was purified by flash chromatography to yield the desired products.

5-Benzyl 1-Methyl ((S)-3-(5-(((Benzyloxy)carbonyl)amino)-methyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)-propanoyl)-L-leucyl-L-glutamate (7a)

Yield (70%), mp 80–82 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.79–0.91 (m, 6 H), 1.38–1.42 (s, 9 H), 1.42–1.49 (m, 1 H), 1.57–1.68 (m, 1 H), 1.83–1.94 (m, 1 H), 1.97–2.08 (m, 1 H), 2.40–2.52 (m, 2 H), 2.98–3.11 (m, 1 H), 3.13–3.25 (m, 1 H), 3.32 (br s, 1 H), 3.55–3.65 (s, 3 H), 4.26–4.35 (s, 2 H), 4.36–4.42 (m, 1 H), 4.52–4.54 (s, 2 H), 4.99–5.12 (s, 4 H), 7.14–7.26 (m, 1 H), 7.27–7.40 (m, 10 H), 7.92–8.05 (m, 1 H), 8.26–8.38 (m, 1 H). HRMS (ESI) calcd for C₃₈H₅₁N₆O₁₁, [M + H]⁺: 767.3616. Found: 767.3612.

5-Benzyl 1-Methyl ((S)-4-(5-(((Benzyloxy)carbonyl)amino)-methyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)-butanoyl)-L-leucyl-L-glutamate (7b)

Yield (67%), mp 94–98 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.86–0.98 (m, 6 H), 1.36–1.49 (s, 9 H), 1.54–1.61 (m, 1 H), 1.62–1.72 (m, 2 H), 1.95–2.07 (m, 2 H), 2.16–2.28 (m, 2 H), 2.36–2.48 (m, 2 H), 2.86–2.98 (m, 2 H), 3.65–3.76 (s, 3 H), 4.11–4.22 (m, 1 H), 4.37–4.48 (m, 1 H), 4.50–4.63 (s, 2 H), 5.07–5.19 (s, 4 H), 5.26–5.38 (m, 1 H), 5.65–5.74 (m, 1 H), 6.94–7.06 (m, 1 H), 7.28–7.39 (m, 10 H), 8.30–8.32 (d, 1 H). HRMS (ESI) calcd for C₃₉H₅₃N₆O₁₁, [M + H]⁺: 781.3772. Found: 781.3765.

5-Benzyl 1-Methyl ((S)-4-(5-(2-(((Benzyloxy)carbonyl)-amino)ethyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)-amino)butanoyl)-L-leucyl-L-glutamate (7c)

Yield (79%), mp 95–97 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.85–0.97 (m, 6 H), 1.39 (s, 9 H), 1.51–1.59 (m, 1 H), 1.61–1.71 (m, 2 H), 1.96–2.07 (m, 2 H), 2.14–2.26 (m, 2 H), 2.38–2.49 (m, 2 H), 2.87–2.96 (m, 2 H), 2.98–3.03 (m, 1 H), 3.60–3.66 (m, 2 H), 3.68–3.73 (s, 3 H), 4.09–4.19 (m, 1 H), 4.33–4.45 (m, 1 H), 4.53–4.63 (m, 1 H), 5.05–5.17 (s, 4 H), 5.3–5.4 (dd, 1H), 5.65 5.75 (dd, 1H), 7.03–7.15 (m, 1 H), 7.26–7.38 (m, 10 H), 8.22–8.30 (dd, 2 H). HRMS (ESI) calcd for C₄₀H₅₅N₆O₁₁, [M + H]⁺: 795.3929. Found: 795.3914.

5-Benzyl 1-Methyl ((S)-4-(5-(3-(((Benzyloxy)carbonyl)-amino)propyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)-amino)butanoyl)-L-leucyl-L-glutamate (7e)

Yield (74%), mp 80–83 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.86–0.99 (m, 6 H), 1.41 (s, 9 H), 1.56–1.63 (m, 1 H), 1.66–1.75 (m, 4 H), 1.80–1.91 (m, 2 H), 1.96–2.09 (m, 2 H), 2.18–2.28 (m, 2 H), 2.37–2.49 (m, 2 H), 2.51–2.62 (m, 2 H), 2.83–2.95 (m, 2 H), 3.29 (dd, *J* = 6.52, 0.66 Hz, 1 H), 3.69 (s, 3 H), 4.05–4.17 (m, 1 H), 4.38–4.47 (m, 1H), 4.54–4.63 (m, 1 H), 5.04–5.17 (s, 4 H), 6.21–6.22 (d, 1 H), 6.42–6.44 (d, 1 H), 7.26–7.27 (m, 1 H), 7.29–

7.39 (m, 10 H), 9.10–9.12 (d, 1 H). HRMS (ESI) calcd for C₄₁H₅₇N₆O₁₁, [M + H]⁺: 809.4085. Found: 809.4081.

Hydrogenolysis of Benzyl Esters 8a–h. General Procedure

To a solution of benzyl ester **7** (12.0 g, 15.09 mmol) in methanol 120 mL (10 mL/g of ester) was added 10% palladium on carbon (0.80 g, 50 mol %), and the mixture was shaken on a Parr hydrogenator for 8 h under 40 atm of H₂ while monitoring the reaction by TLC. The reaction mixture was filtered through Celite, and the Celite bed was washed with methanol. The filtrate was concentrated under reduced pressure to yield compounds **8a–h**.

(6S,9S,12S)-6-((5-(Aminomethyl)-1,3,4-oxadiazol-2-yl)-methyl)-9-isobutyl-12-(methoxycarbonyl)-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazapentadecan-15-oic Acid (8a)

Yield (95%), mp 102–104 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.79–0.92 (m, 6 H), 1.36 (s, 9 H), 1.42–1.49 (m, 2 H), 1.56–1.68 (m, 1 H), 1.76–1.89 (m, 1 H), 1.90–2.02 (m, 1 H), 2.20–2.30 (m, 2 H), 3.01–3.12 (m, 1 H), 3.16–3.29 (m, 1 H), 3.56–3.68 (s, 3 H), 3.84 (s, 2 H), 4.21–4.28 (m, 1 H), 4.30–4.36 (m, 1 H), 4.37–4.43 (m, 1 H), 7.19–7.28 (m, 1 H), 7.28–7.40 (m, 1 H), 7.94–8.07 (m, 1 H), 8.32–8.44 (m, 2 H). HRMS (ESI) calcd for C₂₃H₃₉N₆O₉, [M + H]⁺: 543.2779. Found: 543.2773.

(6S,9S,12S)-6-(2-(5-(Aminomethyl)-1,3,4-oxadiazol-2-yl)-ethyl)-9-isobutyl-12-(methoxycarbonyl)-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazapentadecan-15-oic Acid (8b)

Yield (95%), mp 106–110 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.80–0.93 (d, 6 H), 1.38 (s, 9 H), 1.45 (t, *J* = 7.37 Hz, 2 H), 1.58–1.71 (m, 1 H), 1.75–1.84 (m, 1 H), 1.89–2.02 (m, 3 H), 2.19–2.31 (m, 3 H), 2.50 (dt, *J* = 3.72, 1.87 Hz, 1 H), 2.77–2.88 (m, 2 H), 3.55–3.66 (s, 3 H), 3.86 (s, 2 H), 3.94–4.06 (m, 1 H), 4.21–4.29 (m, 1 H), 4.30–4.39 (m, 1 H), 7.04–7.12 (m, 1 H), 7.90–7.97 (m, 1 H), 8.30–8.41 (m, 1 H). HRMS (ESI) calcd for C₂₄H₄₁N₆O₉, [M + H]⁺: 557.2935. Found: 557.2930.

(6S,9S,12S)-6-(2-(5-(2-Aminoethyl)-1,3,4-oxadiazol-2-yl)-ethyl)-9-(cyclohexylmethyl)-12-(methoxycarbonyl)-2,2-di-methyl-4,7,10-trioxo-3-oxa-5,8,11-triazapentadecan-15-oic Acid (8c)

Yield (94%), mp 90–93 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.83–0.95 (m, 2 H), 1.12–1.20 (m, 2 H), 1.24–1.28 (m, 1 H), 1.37–1.48 (s, 9 H), 1.61–1.74 (m, 6 H), 1.96–2.08 (t, 2 H), 2.15–2.27 (m, 2 H), 2.19 (s, 2 H), 2.36–2.49 (m, 2 H), 2.87–2.96 (m, 2 H), 2.97–3.03 (m, 1 H), 3.60–3.72 (m, 2 H), 3.60–3.72 (s, 3 H), 4.11–4.20 (m, 1 H), 4.50–4.63 (m, 2 H), 7.09–7.18 (m, 1 H), 8.2–8.3 (dd, 2 H). HRMS (ESI) calcd for C₂₅H₄₃N₆O₉, [M + H]⁺: 571.3092. Found: 571.3089.

(6S,9S,12S)-6-(2-(5-(2-Aminoethyl)-1,3,4-oxadiazol-2-yl)-ethyl)-9-(cyclohexylmethyl)-12-(methoxycarbonyl)-2,2-di-methyl-4,7,10-trioxo-3-oxa-5,8,11-triazapentadecan-15-oic Acid (8d)

Yield (94%), mp 119–121 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.79–0.91 (m, 2 H), 1.08–1.20 (m, 4 H), 1.32–1.43 (s, 9 H), 1.44–1.48 (m, 1 H), 1.59–1.67 (m, 4 H), 1.69–1.73 (m, 2 H), 1.87–1.96 (m, 2 H), 1.97–2.02 (m, 1 H), 2.05–2.13 (m, 2 H), 2.48–2.54 (m, 2 H), 2.76–2.86 (m, 2 H), 2.92–3.05 (m, 4 H), 3.10–3.21 (m, 1 H), 3.57–3.68 (s, 3 H), 3.96–4.08 (m, 1 H), 4.17–4.29 (m, 1 H), 4.30–4.43 (m, 1 H) m 7.03–7.14 (m, 1 H) m 7.94–8.07 (m, 1 H) m 8.39–8.46 (m, 1 H). HRMS (ESI) calcd for C₂₈H₄₇N₆O₉, [M + H]⁺: 611.3405. Found: 611.3400.

(6S,9S,12S)-6-(2-(5-(3-Aminopropyl)-1,3,4-oxadiazol-2-yl)-ethyl)-9-isobutyl-12-(methoxycarbonyl)-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazapentadecan-15-oic Acid (8e)

Yield (94%), mp 102–105 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.86–0.97 (m, 6 H), 1.43 (s, 9 H), 1.58–1.65 (m, 1 H), 1.66–1.75 (m, 4 H), 1.83–1.93 (m, 2 H), 1.96–2.09 (m, 2 H), 2.18–2.28 (m, 2 H), 2.37–2.49 (m, 2 H), 2.51–2.62 (m, 2 H), 2.83–2.95 (m, 2 H), 3.29 (dd, *J* = 6.52, 0.66 Hz, 1 H), 3.69 (s, 3 H), 4.05–4.17 (m, 1 H), 4.38–4.47 (m, 1H), 4.54–4.63 (m, 1 H), 6.21–6.22 (d, 1 H), 6.42–6.44 (d, 1 H), 7.26–7.27 (m, 1 H), 9.10–9.12 (d, 1 H). HRMS (ESI) calcd for C₂₆H₄₅N₆O₉, [M + H]⁺: 585.3248. Found: 585.3244.

(6S,9S,12S)-6-(2-(5-(3-Aminopropyl)-1,3,4-oxadiazol-2-yl)-ethyl)-9-(cyclohexylmethyl)-12-(methoxycarbonyl)-2,2-di-methyl-4,7,10-trioxo-3-oxa-5,8,11-triazapentadecan-15-oic Acid (8f)

Yield (96%), mp 117–120 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.78–0.90 (m, 2 H), 1.08–1.19 (m, 2 H), 1.32–1.41 (m, 4 H), 1.37 (s, 9 H), 1.42–1.46 (m, 1 H), 1.59–1.71 (m, 6 H), 1.81–1.86 (m, 2 H), 1.87–1.94 (m, 2 H), 2.03–2.15 (m, 1 H), 2.21–2.29 (m, 2 H), 2.37–2.44 (m, 1 H), 2.50 (dt, *J* = 3.73, 1.89 Hz, 2 H), 3.16–3.22 (m, 1 H), 3.58–3.68 (s, 3 H), 3.84–3.96 (m, 1 H), 4.22–4.28 (m, 1 H), 4.29–4.41 (m, 2 H), 6.88–7.00 (m, 1 H), 7.88–8.00 (m, 1 H), 8.37–8.45 (m, 1 H). HRMS (ESI) calcd for C₂₉H₄₉N₆O₉, [M + H]⁺: 625.3561. Found: 625.3558.

(6S,9S,12S)-6-(2-(5-(4-Aminobutyl)-1,3,4-oxadiazol-2-yl)-ethyl)-9-(cyclohexylmethyl)-12-(methoxycarbonyl)-2,2-di-methyl-4,7,10-trioxo-3-oxa-5,8,11-triazapentadecan-15-oic Acid (8g)

Yield (91%), mp 111–113 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.79–0.91 (m, 2 H), 1.07–1.18 (m, 4 H), 1.33–1.42 (m, 4 H), 1.38 (s, 9 H), 1.44–1.47 (m, 2 H), 1.58–1.68 (m, 4 H), 1.76–1.82 (m, 3 H), 1.84–1.96 (m, 4 H), 2.18–2.30 (t, 2 H), 2.58–2.70 (t, 2 H), 2.76 (t, *J* = 6.41 Hz, 2 H), 3.57–3.69 (s, 3 H), 3.74–3.87 (m, 2 H), 3.91–4.04 (m, 1 H), 4.19–4.30 (m, 1 H), 4.32–4.44 (m, 1 H), 7.05–7.1 (d, 1H), 7.91–8.03 (m, 1 H), 8.41 (d, *J* = 7.32 Hz, 1 H). HRMS (ESI) calcd for C₃₀H₅₁N₆O₉, [M + H]⁺: 639.3718. Found: 639.3715.

(6S,9S,12S)-6-(2-(5-(4-Aminobutyl)-1,3,4-oxadiazol-2-yl)-ethyl)-9-(cyclohexylmethyl)-12-(methoxycarbonyl)-2,2-di-methyl-4,7,10-trioxo-3-oxa-5,8,11-triazapentadecan-15-oic Acid (8h)

Yield (96%), mp 103–106 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.85–0.97 (m, 2 H), 1.12–1.22 (m, 2 H), 1.24–1.28 (m, 2 H), 1.36–1.46 (m, 4 H), 1.42 (s, 9 H), 1.49–1.58 (m, 2 H), 1.63–1.72 (m, 4 H), 1.74–1.76 (m, 2 H), 1.96–2.08 (m, 2 H), 2.16–2.29 (m, 2 H), 2.37–2.49 (m, 2 H), 2.76–2.83 (m, 2 H), 2.86–2.98 (m, 2 H), 3.11–3.24 (m, 2 H), 3.66–3.76 (s, 3 H), 4.0–4.15 (br s, 1H), 4.54–4.64 (m, 2 H), 7.02–7.15 (m, 1 H), 7.92–8.04 (d, 1 H), 8.45 (d, *J* = 7.9 Hz, 1 H). HRMS (ESI) calcd for C₃₁H₅₃N₆O₉, [M + H]⁺: 653.3874. Found: 653.3871.

Synthesis of Macrocyclic Oxadiazole Esters 9a–h. General Procedure

To a solution of compound **8** (2.0 g, 3.5 mmol) in dry DMF (750 mL) were added EDCI (0.87 g, 4.55 mmol, 1.3 equiv), HOBt (0.7 g, 4.55 mmol, 1.3 equiv), DIEA (1.35 g, 10.5 mmol, 3.0 equiv), and the mixture was stirred for 18 h at room temperature while monitoring the reaction by TLC. The solvent was removed, and the residue was partitioned between ethyl acetate (200 mL) and 10% citric acid (2 × 50 mL). The ethyl acetate layer was further washed with saturated aqueous NaHCO₃ (2 × 50 mL), followed by saturated NaCl (50 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude product was purified by flash chromatography to yield compounds **9a–h**.

Methyl (7S,10S,13S)-13-((*tert*-Butoxycarbonyl)amino)-10-isobutyl-4,9,12-trioxo-3,8,11-triaza-1(2,5)-oxadiazolacyclote-tradecaphane-7-carboxylate (9a)

Yield (60%), mp 160–163 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.88 (dd, *J* = 12.52, 6.57 Hz, 6 H), 1.43 (s, 9 H), 1.59–1.70 (m, 2 H), 2.09–2.18 (m, 1 H), 2.20–2.28 (m, 1 H), 2.35–2.45 (m, 1 H), 3.12–3.21 (m, 1 H), 3.27 (dd, *J* = 15.01, 7.01 Hz, 1 H), 3.31–3.40 (m, 1 H), 3.56–3.69 (m, 1 H), 3.56–3.69 (s, 3 H), 4.07–4.18 (m, 1 H), 4.27–4.39 (m, 1 H), 4.39–4.50 (m, 1 H), 4.50–4.61 (m, 1 H), 4.78 (dd, *J* = 16.01, 7.91 Hz, 1 H), 6.17 (dd, *J* = 7.88, 0.12 Hz, 1 H), 7.31–7.43 (m, 1 H), 8.16–8.24 (m, 1 H), 8.27 (d, *J* = 8.45 Hz, 1 H). HRMS (ESI) calcd for C₂₃H₃₆N₆O₈Na, [M + Na]⁺: 547.2492. Found: 547.2504.

Methyl (7S,10S,13S)-13-((*tert*-Butoxycarbonyl)amino)-10-isobutyl-4,9,12-trioxo-3,8,11-triaza-1(2,5)-oxadiazola-cyclopentadecaphane-7-carboxylate (9b)

Yield (67%), mp 177–180 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.80–0.93 (m, 6 H), 1.33–1.41 (s, 9 H), 1.42–1.47 (m, 2 H), 1.57–1.69 (m, 1 H), 1.81–1.93 (m, 2 H), 1.94–2.04 (m, 2 H), 2.18–2.27 (m, 1 H), 2.30–2.40 (m, 1 H), 2.44–2.56 (m, 2 H), 2.78–2.90 (t, 2 H), 3.29–3.40 (m, 1 H), 3.55–3.67 (s, 3 H), 3.98–4.08 (m, 1 H), 4.38–4.46 (s, 2 H), 7.03–7.15 (m, 1 H), 7.82–7.93 (m, 1 H). HRMS (ESI) calcd for C₂₄H₃₈N₆O₈Na, [M + Na]⁺: 561.2649. Found: 561.2643.

Methyl 14-((*tert*-Butoxycarbonyl)amino)-11-isobutyl-5,10,13-trioxo-4,9,12-triaza-1(2,5)-oxadiazolacyclohexa-decaphane-8-carboxylate (9c)

Yield (57%), mp 155–157 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.80–0.93 (m, 6 H), 1.33–1.45 (s, 9 H), 1.84–1.97 (m, 2 H), 1.99–2.04 (m, 1 H), 2.78 (br s, 1 H), 2.79 (d, *J* = 5.08 Hz, 1 H), 2.85–2.97 (m, 2 H), 3.29–3.41 (m, 8 H), 3.56–3.68 (m, 3 H), 3.56–3.68 (m, 3 H),

4.37–4.45 (m, 1 H), 6.98–7.02 (dd, 1H), 7.30–7.35 (dd, 1H), 7.89–8.00 (dd, 1 H), 8.21 (dd, $J = 11.55, 8.42$ Hz, 1 H). HRMS (ESI) calcd for $C_{25}H_{40}N_6O_8Na$, $[M + Na]^+$: 575.2805. Found: 575.2824.

Methyl (8S,11S,14S)-14-((*tert*-Butoxycarbonyl)amino)-11-(cyclohexylmethyl)-5,10,13-trioxo-4,9,12-triaza-1(2,5)-oxadiazolacyclohexadecaphane-8-carboxylate (9d)

Yield (70%), mp 197–200 °C. 1H NMR (400 MHz, DMSO- d_6) δ 0.80–0.91 (m, 2 H), 1.07–1.20 (m, 3 H), 1.33–1.41 (m, 6 H), 1.38 (s, 9 H), 1.42–1.46 (m, 2 H), 1.58–1.67 (m, 4 H), 1.89–2.01 (m, 1 H), 2.47–2.56 (m, 2 H), 2.78–2.84 (m, 1 H), 2.86–2.93 (t, 2 H), 3.30–3.43 (t, 2 H), 3.55–3.67 (s, 3 H), 4.03 (d, $J = 7.13$ Hz, 1 H), 4.43–4.50 (t, 2 H), 7.89–8.00 (m, 1 H), 7.15 (dd, 1H), 7.3 (dd, 1H), 8.21 (dd, $J = 11.55, 8.42$ Hz, 1 H). HRMS (ESI) calcd for $C_{28}H_{44}N_6O_8Na$, $[M + Na]^+$: 615.3118. Found: 615.3112.

Methyl (9S,12S,15S)-15-((*tert*-Butoxycarbonyl)amino)-12-isobutyl-6, 11, 14-trioxo-5, 10, 13-triaza-1 (2,5) -oxadiazolacycloheptadecaphane-9-carboxylate(9e)

Yield (72%), mp 218–220 °C. 1H NMR (400 MHz, DMSO- d_6) δ 0.81–0.93 (m, 6 H), 1.35 (s, 9 H), 1.62 (d, $J = 6.79$ Hz, 1 H), 1.80–1.89 (m, 4 H), 2.49 (br s, 1 H), 2.50 (dt, $J = 3.75, 1.86$ Hz, 4 H), 2.66–2.72 (m, 1 H), 2.73–2.79 (m, 2 H), 3.32 (s, 2 H), 3.32–3.35 (m, 4 H), 3.62 (s, 3 H), 4.37 (br s, 1 H), 4.37–4.44 (m, 1 H), 8.16–8.22 (m, 1 H), 8.39–8.46 (m, 1 H), 9.95 (s, 1 H). HRMS (ESI) calcd for $C_{26}H_{42}N_6O_8$, $[M + Na]^+$: 589.2962. Found: 589.2962.

Methyl (9S,12S,15S)-15-((*tert*-Butoxycarbonyl)amino)-12-(cyclohexylmethyl)-6,11,14-trioxo-5,10,13-triaza-1(2,5)-oxadiazolacycloheptadecaphane-9-carboxylate (9f)

Yield (65%), mp 177–180 °C. 1H NMR (400 MHz, DMSO- d_6) δ 0.79–0.91 (m, 2 H), 1.08–1.20 (m, 6 H), 1.40–1.43 (s, 9 H), 1.56–1.69 (m, 3 H), 1.75–1.88 (m, 4 H), 1.97–2.02 (m, 2 H), 2.09–2.21 (m, 1 H), 2.47–2.53 (m, 2 H), 2.68–2.78 (m, 3 H), 2.85–2.96 (m, 2 H), 3.17 (d, $J = 4.83$ Hz, 1 H), 3.33 (t, 2 H), 3.63–3.68 (s, 3 H), 3.97–4.06 (m, 2 H), 4.33–4.42 (m, 1 H), 6.88–7.00 (m, 1 H), 7.88–8.00 (m, 1 H), 8.37–8.45 (m, 1 H). HRMS (ESI) calcd for $C_{29}H_{46}N_6O_8Na$, $[M + Na]^+$: 629.3275. Found: 629.3267.

Methyl (4S,7S,10S)-4-((*tert*-Butoxycarbonyl)amino)-7-(cyclohexylmethyl)-5, 8, 13-trioxo-6, 9, 14-triaza-1 (2, 5)-oxadiazolacyclooctadecaphane-10-carboxylate (9g)

Yield (51%), mp 98–101 °C. 1H NMR (400 MHz, DMSO- d_6) δ 0.83–0.95 (m, 2 H), 1.09–1.21 (m, 3 H), 1.32–1.43 (m, 5 H), 1.36 (s, 9 H) 1.56–1.69 (m, 4 H), 1.75–1.88 (m, 4 H), 1.96–2.07 (m, 2 H), 2.09–2.23 (m, 2 H), 2.40–2.47 (m, 1 H), 2.49–2.53 (m, 1 H), 2.66–2.79 (m, 3 H), 2.84–2.93 (m, 1 H), 3.56–3.68 (s, 3 H), 3.95–4.06 (m, 2 H), 4.36–4.44 (m, 2 H), 6.66–6.75 (dd, $J = 8.4$ Hz, 1 H), 8.14–8.24 (dd, $J = 8.2$ Hz, 1 H), 8.38–8.45 (dd, $J = 8.2$ Hz, 1 H), 9.93–9.98 (m, 1 H). HRMS (ESI) calcd for $C_{30}H_{48}N_6O_8Na$, $[M + Na]^+$: 643.3431. Found: 643.3412.

Methyl (4S,7S,10S)-4-((*tert*-Butoxycarbonyl)amino)-7-(cyclohexylmethyl)-5, 8, 13-trioxo-6, 9, 14-triaza-1 (2, 5)-oxadiazolacyclooctadecaphane-10-carboxylate (9h)

Yield (51%), mp 181–183 °C. 1H NMR (400 MHz, $CDCl_3$) δ 0.77–0.90 (m, 2 H), 0.90–1.01 (m, 2 H), 1.12–1.20 (m, 4 H), 1.24–1.35 (m, 4 H), 1.37–1.46 (m, 6 H), 1.43 (s, 9 H), 1.50–

1.58 (m, 2 H), 1.60–1.71 (m, 4 H), 1.72–1.80 (m, 3 H), 2.23–2.32 (m, 2 H), 2.88 (ddd, $J=10.79, 7.62, 4.64$ Hz, 2 H), 2.98–3.10 (m, 2 H), 3.64–3.76 (s, 3 H), 4.51–4.61 (m, 1 H), 6.83–6.95 (m, 1 H), 7.39–7.50 (d, 1 H), 7.6–7.7 (d, 1 H), 7.8–7.9 (d, 1 H). HRMS (ESI) calcd for $C_{31}H_{50}N_6O_8Na$, $[M + Na]^+$: 657.3588. Found: 657.3590.

Synthesis of Alcohols 10a–h. General Procedure

To a solution of ester **9** (3.25 mmol) in anhydrous THF (25 mL) was added dropwise lithium borohydride (2 M in THF, 4.9 mL, 9.75 mmol) followed by absolute ethyl alcohol (15 mL), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then acidified by adding 1.5 M potassium bisulfate until the pH of the solution was ~3. Removal of the solvent left a residue which was taken up in ethyl acetate (150 mL). The organic layer was washed with brine (25 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to yield compounds **10a–h**.

tert-Butyl ((7S,10S,13S)-7-(Hydroxymethyl)-10-isobutyl-4,9,12-trioxo-3,8,11-triaza-1(2,5)-oxadiazolacylotetra-decaphane-13-yl)carbamate (10a)

170d °C, yield (82%). 1H NMR (400 MHz, DMSO- d_6) δ 0.79–0.91 (m, 6 H), 1.15–1.20 (m, 1 H), 1.33–1.45 (s, 9 H), 1.53–1.65 (m, 2 H), 1.73–1.85 (m, 1 H), 1.86–1.96 (m, 1 H), 1.96–2.03 (m, 1 H), 2.15–2.27 (m, 1 H), 2.38 (br s, 1 H), 2.51 (dq, $J=3.48, 1.74, 1.74, 1.74$ Hz, 1 H), 2.85–2.97 (m, 1 H), 3.19–3.26 (m, 1 H), 3.28–3.40 (m, 1 H), 3.62–3.73 (m, 1 H), 3.99–4.08 (m, 1 H), 4.27 (br s, 2 H), 7.31–7.38 (m, 1 H), 7.39–7.45 (m, 1 H), 7.51–7.62 (m, 1 H), 7.66–7.76 (m, 1 H), 7.90–8.02 (m, 1 H). HRMS (ESI) calcd for $C_{22}H_{37}N_6O_7$, $[M + H]^+$: 497.2724. Found: 497.2710

tert-Butyl ((7S,10S,13S)-7-(Hydroxymethyl)-10-isobutyl-4,9,12-trioxo-3,8,11-triaza-1(2,5)-oxadiazolacyclopenta-decaphane-13-yl)carbamate (10b)

Yield (80%), mp 183–186 °C. 1H NMR (400 MHz, DMSO- d_6) δ 0.78–0.90 (m, 6 H), 1.15–1.23 (m, 1 H), 1.38 (s, 9 H), 1.57–1.63 (m, 1 H), 1.70–1.81 (m, 1 H), 1.87–1.95 (m, 1 H), 2.48–2.56 (m, 3 H), 2.77–2.86 (m, 1 H), 2.88–2.98 (m, 1 H), 3.20–3.26 (m, 1 H), 3.29–3.42 (m, 2 H), 3.59–3.66 (m, 1 H), 3.66–3.75 (m, 1 H), 4.27 (br s, 2 H), 4.40–4.50 (m, 3 H), 6.99–7.03 (d, 1 H), 7.22–7.29 (d, 1 H), 7.62–7.70 (d, 1 H), 7.90–8.00 (d, 1 H). HRMS (ESI) calcd for $C_{23}H_{38}N_6O_7Na$, $[M + Na]^+$: 533.2700. Found: 533.2721.

tert-Butyl ((8S,11S,14S)-8-(Hydroxymethyl)-11-isobutyl-5,10,13-trioxo-4,9,12-triaza-1(2,5)-oxadiazolacyclohexa-decaphane-14-yl)carbamate (10c)

Yield (85%), mp 181–184 °C. 1H NMR (400 MHz, DMSO- d_6) δ 0.78–0.90 (m, 6 H), 1.15–1.23 (m, 1 H), 1.38 (br s, 9 H), 1.57–1.63 (m, 1 H), 1.70–1.81 (m, 1 H), 1.87–1.95 (m, 1 H), 1.97–2.09 (m, 1 H), 1.97–2.09 (m, 1 H), 2.48–2.56 (m, 3 H), 2.77–2.86 (m, 1 H), 2.88–2.98 (m, 2 H), 3.20–3.26 (m, 1 H), 3.29–3.42 (m, 4 H), 3.59–3.66 (m, 1 H), 3.66–3.75 (m, 1 H), 4.27 (br s, 2 H), 6.94–6.96 (d, 1 H), 7.09–7.13 (d, 1 H), 7.63–7.72 (d, 1 H), 7.90–8.02 (d, 1 H). HRMS (ESI) calcd for $C_{24}H_{40}N_6O_7Na$, $[M + Na]^+$: 547.2856. Found: 547.2870.

***tert*-Butyl ((8*S*,11*S*,14*S*)-11-(Cyclohexylmethyl)-8-(hydroxymethyl)-5, 10, 13-trioxo-4, 9, 12-triaza-1 (2, 5)-oxadiazolacyclohexadecaphane-14-yl)carbamate (10d)**

Yield (88%), mp 188–191 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.78–0.91 (m, 4 H), 1.07–1.18 (m, 6 H), 1.43–1.46 (s, 9 H), 1.56–1.67 (m, 1 H), 1.72–1.84 (m, 3 H), 1.97–2.09 (m, 2 H), 2.22–2.30 (m, 2 H), 2.44–2.50 (m, 2 H), 2.85–2.97 (m, 2 H), 3.55–3.67 (m, 5 H), 3.92–4.02 (m, 2 H), 4.25–4.37 (m, 2 H), 6.53 (br s, 1 H), 7.04–7.16 (m, 1 H), 7.67–7.80 (m, 1 H), 7.86–7.97 (m, 1 H). HRMS (ESI) calcd for C₂₇H₄₅N₆O₇, [M + H]⁺: 565.3350. Found: 565.3361.

***tert*-Butyl ((9*S*,12*S*,15*S*)-9-(Hydroxymethyl)-12-isobutyl-6,11,14-trioxo-5,10,13-triaza-1(2,5)-oxadiazolacyclohepta-decaphane-15-yl)carbamate (10e)**

Yield (85%), mp 168–172 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.85–0.97 (m, 6 H), 1.09–1.15 (m, 2 H), 1.16–1.23 (m, 2 H), 1.29 (br s, 1 H), 1.38–1.47 (s, 9 H), 1.58 (br s, 1 H), 1.58–1.68 (m, 2 H), 2.48–2.60 (m, 4 H), 2.67–2.76 (m, 1 H), 2.81–2.93 (m, 4 H), 3.48–3.61 (m, 3 H), 4.30–4.50 (m, 3 H), 7.36 (br s, 1 H), 7.37–7.45 (m, 2 H), 7.60–7.64 (d, 1 H). HRMS (ESI) calcd for C₂₅H₄₃N₆O₇, [M + H]⁺: 539.3193. Found: 539.0371.

***tert*-Butyl ((9*S*,12*S*,15*S*)-12-(Cyclohexylmethyl)-9-(hydroxymethyl)-6, 11, 14-trioxo-5, 10, 13-triaza-1 (2, 5) -oxadiazolacycloheptadecaphane-15-yl)carbamate (10f)**

Yield (90%), mp 191–194 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.80–0.92 (m, 3 H), 1.08–1.20 (m, 4 H), 1.23–1.30 (m, 2 H), 1.35–1.47 (s, 9 H), 1.57–1.69 (m, 4 H), 1.81–1.85 (m, 1 H), 1.87–1.96 (m, 2 H), 1.96–2.07 (m, 2 H), 2.15 (br s, 2 H), 2.48–2.60 (m, 4 H), 2.67–2.76 (m, 1 H), 2.89–2.96 (m, 1 H), 3.54–3.62 (m, 3 H), 3.64–3.67 (m, 1 H), 4.18–4.30 (br s, 2 H), 7.31–7.33 (d, 1 H), 7.66–7.68 (d, 1 H), 7.81–7.84 (d, 1 H), 7.94–7.97 (d, 1 H). HRMS (ESI) calcd for C₂₈H₄₆N₆O₇Na, [M + Na]⁺: 601.3326. Found: 601.0944.

***tert*-Butyl ((4*S*,7*S*,10*S*)-7-(Cyclohexylmethyl)-10-(hydroxy-methyl)-5,8,13-trioxo-6,9,14-triaza-1(2,5)-oxadiazolacycloocta-decaphane-4-yl)carbamate (10g)**

Yield (92%), mp 139–141 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.79–0.92 (m, 2 H), 1.05–1.14 (m, 5 H), 1.23–1.30 (m, 2 H), 1.43–1.46 (s, 9 H), 1.56–1.67 (m, 4 H), 1.82–1.87 (m, 2 H), 1.89–1.97 (m, 3 H), 2.15–2.26 (m, 1 H), 2.48–2.59 (m, 2 H), 2.67–2.73 (m, 1 H), 2.74–2.86 (m, 2 H), 2.88–2.95 (m, 1 H), 3.22–3.27 (m, 1 H), 3.30–3.39 (m, 2 H), 3.41–3.47 (m, 1 H), 3.60–3.71 (m, 1 H), 3.92–4.02 (m, 2 H), 4.25–4.37 (m, 2 H), 6.53 (br s, 1 H), 7.04–7.16 (m, 1 H), 7.67–7.80 (m, 1 H), 7.86–7.97 (m, 1 H). HRMS (ESI) calcd for C₂₉H₄₉N₆O₇, [M + H]⁺: 593.3663. Found: 593.3660.

***tert*-Butyl ((4*S*,7*S*,10*S*)-7-(Cyclohexylmethyl)-10-(hydroxymethyl)-5, 8, 13-trioxo-6, 9, 14-triaza-1 (2, 5)-oxadiazolacyclononadecaphane-4-yl)carbamate (10h)**

Yield (90%), mp 142–145 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.84–0.96 (m, 2 H), 1.12–1.21 (m, 5 H), 1.24–1.28 (m, 2 H), 1.37–1.48 (s, 9 H), 1.60–1.71 (m, 7 H), 1.84 (d, *J* = 2.64 Hz, 1 H), 1.84–1.96 (m, 2 H), 1.96–2.07 (m, 2 H), 2.09 (s, 1 H), 2.16–2.28 (m, 2 H), 2.28–2.40 (m, 2 H), 2.80–2.92 (m, 2 H), 2.96 (br s, 2 H), 3.55–3.67 (m, 1 H), 3.75 (br s, 1 H), 4.12 (q, *J* = 7.11 Hz, 1 H), 4.40–4.50 (m, 2 H), 7.26–7.35 (m, 2 H), 7.40–7.53 (m, 2 H), 7.73–7.81 (m, 1

H), 7.81–7.93 (m, 1 H). HRMS (ESI) calcd for $C_{30}H_{50}N_6O_7Na$, $[M + Na]^+$: 629.3639. Found: 629.3638.

Synthesis of Compounds 13a–d. General Procedure

To a solution of compound **4** (12.0 g, 26.75 mmol) in dry DMF (120 mL) were added EDCI (6.7 g, 34.78 mmol, 1.3 equiv), HOBt (5.29 g, 34.78 mmol, 1.3 equiv), and the mixture was stirred for 30 min at room temperature. In a separate flask, a solution of (L)-cyclohexyl alanine methyl ester hydrochloride **12** (5.93 g, 26.75 mmol) in dry DMF (100 mL) cooled to 0–5 °C was treated with diisopropylethylamine (13.83 g, 107 mmol, 4.0 equiv), stirred for 30 min, and then added to the reaction mixture above. The solution was stirred for 16 h while monitoring the reaction by TLC. The solvent was removed, and the residue was partitioned between ethyl acetate (300 mL) and 5% aqueous HCl (2 × 120 mL). The ethyl acetate layer was further washed with saturated $NaHCO_3$ (2 × 120 mL), followed by saturated NaCl (120 mL). The organic layer was dried over anhydrous Na_2SO_4 , filtered, and concentrated. The crude product was purified by flash chromatography to yield compounds **13a–d**.

Methyl (S)-2-((S)-4-(5-(2-(((Benzyloxy)carbonyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)-butanamido)-3-cyclohexylpropanoate (13a)

Oil, yield (80%). 1H NMR (400 MHz, $CDCl_3$) δ 0.85–0.98 (m, 2 H), 1.13–1.22 (m, 3 H), 1.23–1.26 (m, 1 H), 1.34–1.46 (m, 1H), 1.40 (s, 9 H), 1.60–1.72 (m, 6 H), 2.01–2.13 (m, 2 H), 2.18–2.31 (m, 1 H), 2.96–3.08 (m, 4 H), 3.62–3.74 (m, 2 H), 3.70 (s, 3 H), 4.15–4.26 (m, 1 H), 4.54–4.66 (m, 1 H), 5.05–5.17 (s, 2 H), 5.40–5.49 (m, 1 H), 5.71–5.84 (m, 1 H), 7.27–7.40 (m, 5 H). HRMS (ESI) calcd for $C_{31}H_{46}N_5O_8$, $[M + H]^+$: 616.3346. Found: 616.3404.

Methyl (S)-2-((S)-4-(5-(3-(((Benzyloxy)carbonyl)amino)-propyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)-butanamido)-3-cyclohexylpropanoate (13b)

Oil, yield (81%). 1H NMR (400 MHz, $CDCl_3$) δ 0.84–0.96 (m, 3 H), 1.14–1.26 (m, 4 H), 1.34–1.46 (m, 3 H), 1.42 (s, 9 H), 1.59–1.72 (m, 3 H), 1.95–2.07 (m, 4 H), 2.23–2.35 (m, 1 H), 2.88 (t, $J = 7.40$ Hz, 2 H), 2.93–3.05 (m, 2 H), 3.23–3.36 (m, 2 H), 3.72–3.77 (s, 3 H), 4.17–4.29 (m, 1 H), 4.55–4.67 (m, 1 H), 5.09 (s, 2 H), 5.42 (d, $J = 7.32$ Hz, 1 H), 7.27–7.39 (m, 5 H). HRMS (ESI) calcd for $C_{32}H_{48}N_5O_8$, $[M + H]^+$: 630.3503. Found: 630.3500.

Methyl (S)-2-((S)-4-(5-(4-(((Benzyloxy)carbonyl)amino)-butyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)-butanamido)-3-cyclohexylpropanoate (13c)

Oil, yield (81%). 1H NMR (400 MHz, $CDCl_3$) δ 0.87–0.97 (m, 2 H), 1.14–1.26 (m, 2 H), 1.33–1.44 (s, 9 H), 1.58–1.63 (m, 2 H), 1.65–1.72 (m, 4 H), 1.77–1.85 (m, 2 H), 2.01–2.12 (m, 2 H), 2.22–2.34 (m, 2 H), 2.78–2.90 (m, 2 H), 2.98–3.08 (m, 1 H), 3.18–3.27 (m, 2 H), 3.68–3.75 (m, 2 H), 3.71 (s, 3 H), 4.19–4.27 (m, 1 H), 4.55–4.62 (m, 1 H), 5.01 (br s, 1 H), 5.09 (s, 2 H), 5.41 (d, $J = 7.66$ Hz, 1 H), 7.13–7.24 (m, 1 H), 7.26–7.39 (m, 5 H). HRMS (ESI) calcd for $C_{33}H_{50}N_5O_8$, $[M + H]^+$: 644.3659. Found: 644.3652.

Methyl (S)-2-((R)-4-(5-(5-(((Benzyloxy)carbonyl)amino)-pentyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)-butanamido)-3-cyclohexylpropanoate (13d)

Oil, yield (79%). ¹H NMR (400 MHz, CDCl₃) δ 0.86–0.99 (m, 2 H), 1.14–1.20 (m, 2 H), 1.21–1.28 (m, 2 H), 1.35–1.47 (s, 9 H), 1.52–1.59 (m, 2 H), 1.61–1.72 (m, 6 H), 1.74–1.82 (m, 2 H), 1.96–2.07 (m, 2 H), 2.22–2.35 (m, 1 H), 2.77–2.89 (m, 2 H), 2.93–3.05 (m, 2 H), 3.12–3.25 (m, 2 H), 3.67–3.78 (s, 3 H), 4.24–4.30 (br s, 1 H), 4.55–4.67 (m, 1 H), 5.04–5.16 (s, 2 H), 5.35–5.55 (br s, 1H), 6.98–7.0 (br s, 1 H), 7.27–7.39 (m, 5 H). HRMS (ESI) calcd for C₃₄H₅₂N₅O₈, [M + H]⁺: 658.3816. Found: 658.3879.

Synthesis of Compounds 14a–d. General Procedure

A solution of ester **13** (25 mmol) in THF (40 mL) was treated with 1 M LiOH in aqueous ethanol (50 mL). The reaction mixture was stirred for 3 h at room temperature, and the disappearance of the ester was monitored by TLC. Most of the solvent was evaporated off, and the residue was diluted with water (25 mL). The solution was acidified to pH ≈ 3 using 5% hydrochloride acid (25 mL), and the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to yield compounds **14a–d**.

(S)-2-((S)-4-(5-(2-(((Benzyloxy)carbonyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanamido)-3-cyclohexylpropanoic Acid (14a)

Yield (95%), mp 59–62 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.85–0.98 (m, 2 H), 1.13–1.22 (m, 3 H), 1.23–1.26 (m, 1 H), 1.34–1.46 (m, 1H), 1.40 (s, 9 H), 1.60–1.72 (m, 6 H), 2.01–2.13 (m, 2 H), 2.18–2.31 (m, 1 H), 2.96–3.08 (m, 4 H), 3.62–3.74 (m, 2 H), 4.15–4.26 (m, 1 H), 4.54–4.66 (m, 1 H), 5.05–5.17 (s, 2 H), 5.40–5.49 (m, 1 H), 5.71–5.84 (m, 1 H), 7.27–7.40 (m, 5 H). HRMS (ESI) calcd for C₃₀H₄₄N₅O₈, [M + H]⁺: 602.3190. Found: 602.3214.

(S)-2-((S)-4-(5-(3-(((Benzyloxy)carbonyl)amino)propyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanamido)-3-cyclohexylpropanoic Acid (14b)

Oil, yield (95%). ¹H NMR (400 MHz, CDCl₃) δ 0.84–0.96 (m, 3 H), 1.14–1.26 (m, 4 H), 1.34–1.46 (m, 3 H), 1.42 (s, 9 H), 1.59–1.72 (m, 3 H), 1.95–2.07 (m, 4 H), 2.23–2.35 (m, 1 H), 2.88 (t, *J* = 7.40 Hz, 2 H), 2.93–3.05 (m, 2 H), 3.23–3.36 (m, 2 H), 4.17–4.29 (m, 1 H), 4.55–4.67 (m, 1 H), 5.09 (s, 2 H), 5.42 (d, *J* = 7.32 Hz, 1 H), 7.27–7.39 (m, 5 H). HRMS (ESI) calcd for C₃₁H₄₆N₅O₈, [M + H]⁺: 616.3346. Found: 616.3362.

(S)-2-((R)-4-(5-(4-(((Benzyloxy)carbonyl)amino)butyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanamido)-3-cyclohexylpropanoic Acid (14c)

Oil, yield (98%). ¹H NMR (400 MHz, CDCl₃) δ 0.87–0.98 (m, 2 H), 1.14–1.26 (m, 2 H), 1.39–1.50 (s, 9 H), 1.56–1.62 (m, 2 H), 1.64–1.71 (m, 4 H), 1.74–1.82 (m, 4 H), 2.02–2.15 (m, 2 H), 2.23–2.34 (m, 1 H), 2.81–2.91 (m, 2 H), 2.92–3.00 (m, 1 H), 3.14–3.26 (m, 2 H), 4.30–4.42 (m, 1 H), 4.57–4.69 (m, 1 H), 5.06–5.18 (s, 2 H), 5.18–5.30 (m, 1 H), 5.43–5.53 (m, 1 H), 5.53–5.65 (m, 1 H), 6.66–6.78 (m, 1 H), 7.26–7.39 (m, 5 H). HRMS (ESI) calcd for C₃₂H₄₈N₅O₈, [M + H]⁺: 630.3503. Found: 630.3570.

(S)-2-((R)-4-(5-(5-(((Benzyloxy)carbonyl)amino)pentyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanamido)-3-cyclohexylpropanoic Acid (14d)

Oil, yield (98%). ¹H NMR (400 MHz, CDCl₃) δ 0.86–0.99 (m, 2 H), 1.14–1.20 (m, 2 H), 1.21–1.28 (m, 2 H), 1.35–1.47 (s, 9 H), 1.52–1.59 (m, 2 H), 1.61–1.72 (m, 6 H), 1.74–1.82 (m, 2 H), 1.96–2.07 (m, 2 H), 2.22–2.35 (m, 1 H), 2.77–2.89 (m, 2 H), 2.93–3.05 (m, 2 H), 3.12–3.25 (m, 2 H), 4.24–4.30 (br s, 1 H), 4.55–4.67 (m, 1 H), 5.04–5.16 (s, 2 H), 5.35–5.55 (br s, 1H), 6.98–7.0 (br s, 1 H), 7.27–7.39 (m, 5 H). HRMS (ESI) calcd for C₃₃H₅₀N₅O₈, [M + H]⁺: 644.3659. Found: 644.3742.

Synthesis of Compounds 7d and 7f–h. General Procedure

To a solution of compound **14** (15.0 g, 24.92 mmol) in dry DMF (150 mL) were added EDCI (6.2 g, 32.39 mmol, 1.3 equiv), HOBt (4.96 g, 32.39 mmol, 1.3 equiv), and the reaction mixture was stirred for 30 min at room temperature. In a separate flask, a solution of (L)-Glu(OBzl) methyl ester hydrochloride **5** (7.17 g, 24.92 mmol) in dry DMF (80 mL) cooled to 0–5 °C was treated with diisopropylethyl-amine (DIEA) (12.88 g, 99.68 mmol, 4.0 equiv), stirred for 30 min, and then added to the reaction mixture above. The reaction mixture was stirred for 16 h while monitoring the reaction by TLC. The solvent was removed, and the residue was partitioned between ethyl acetate (400 mL) and 5% aqueous HCl (2 × 120 mL). The ethyl acetate layer was further washed with saturated aqueous NaHCO₃ (2 × 120 mL), followed by saturated NaCl (120 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude was purified by flash chromatography to yield compounds **7d** and **7f–h**.

5-Benzyl 1-Methyl ((S)-2-((S)-4-(5-(2-(((Benzyloxy)carbonyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanamido)-3-cyclohexylpropanoyl)-L-glutamate (7d)

Yield (75%), mp 54–57 °C ¹H NMR (400 MHz, CDCl₃) δ 0.83–0.95 (m, 2 H), 1.12–1.20 (m, 2 H), 1.24–1.28 (m, 1 H), 1.37–1.48 (s, 9 H), 1.61–1.74 (m, 6 H), 1.96–2.08 (t, 2 H), 2.15–2.27 (m, 2 H), 2.19 (s, 2 H), 2.36–2.49 (m, 2 H), 2.87–2.96 (m, 2 H), 2.97–3.03 (m, 1 H), 3.60–3.72 (m, 2 H), 3.60–3.72 (s, 3 H), 4.11–4.20 (m, 1 H), 4.50–4.63 (m, 2 H), 5.06–5.18 (s,s, 4 H), 7.09–7.18 (m, 1 H), 7.29–7.39 (m, 10 H), 8.2–8.3 (dd, 2 H). HRMS (ESI) calcd for C₄₃H₅₉N₆O₁₁, [M + H]⁺: 835.4242. Found: 835.4238.

(S)-5-Benzyl 1-Methyl (2-(4-(5-(3-(((Benzyloxy)carbonyl)amino)propyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)butanamido)-3-cyclohexylpropanoyl)glutamate (7f)

Oil, yield (70%). ¹H NMR (400 MHz, CDCl₃) δ 0.82–0.94 (m, 2 H), 1.08–1.20 (m, 3 H), 1.22–1.26 (m, 1 H), 1.28–1.33 (m, 1 H), 1.35–1.44 (m, 1 H), 1.39 (s, 9 H), 1.58–1.70 (m, 5 H), 1.94–2.06 (m, 4 H), 2.14–2.26 (m, 2 H), 2.36–2.48 (m, 2 H), 2.81–2.93 (m, 3 H), 3.19–3.31 (m, 1 H), 3.61–3.72 (m, 3 H), 4.07–4.18 (m, 1 H), 4.40–4.49 (m, 2 H), 4.50–4.60 (m, 2 H), 5.02–5.14 (m, 4 H), 7.02–7.14 (m, 1 H), 7.25–7.37 (m, 10 H). HRMS (ESI) calcd for C₄₄H₆₁N₆O₁₁, [M + H]⁺: 849.4398. Found: 849.4393.

5-Benzyl 1-Methyl ((S)-2-((S)-4-(5-(4-(((Benzyloxy)carbonyl)-amino)butyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)-amino)butanamido)-3-cyclohexylpropanoyl)-L-glutamate (7g)

Yield (75%), mp 75–77 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.85–0.97 (m, 2 H), 1.10–1.22 (m, 2 H), 1.38–1.48 (s, 9 H), 1.58–1.71 (m, 5 H), 1.78–1.83 (m, 4 H), 1.96–2.09 (m, 2 H), 2.16–2.28 (m, 2 H), 2.37–2.48 (m, 2 H), 2.79–2.86 (m, 2 H), 2.87–2.97 (m, 2 H), 3.15–3.27 (m, 2 H), 3.66–3.77 (s, 3 H), 4.41–4.51 (m, 1 H), 4.53–4.62 (m, 1 H), 5.05–5.16 (m, 4 H), 7.03–7.16 (m, 1 H), 7.26–7.39 (m, 10 H). HRMS (ESI) calcd for C₄₅H₆₃N₆O₁₁, [M + H]⁺: 863.4555. Found: 863.4549.

5-Benzyl 1-Methyl ((S)-2-((S)-4-(5-(5-(((Benzyloxy)carbonyl)-amino)pentyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)-amino)butanamido)-3-cyclohexylpropanoyl)-L-glutamate (7h)

Yield (80%), mp 59–62 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.85–0.97 (m, 2 H), 1.12–1.22 (m, 2 H), 1.24–1.28 (m, 2 H), 1.36–1.46 (m, 4 H), 1.42 (s, 9 H), 1.49–1.58 (m, 2 H), 1.63–1.72 (m, 4 H), 1.74–1.76 (m, 2 H), 1.96–2.08 (m, 2 H), 2.16–2.29 (m, 2 H), 2.37–2.49 (m, 2 H), 2.76–2.83 (m, 2 H), 2.86–2.98 (m, 2 H), 3.11–3.24 (m, 2 H), 3.66–3.76 (s, 3 H), 4.0–4.15 (br s, 1H), 4.54–4.64 (m, 2 H), 5.04–5.16 (m, 4 H), 7.02–7.15 (m, 1 H), 7.27–7.39 (m, 10 H). HRMS (ESI) calcd for C₄₆H₆₅N₆O₁₁, [M + H]⁺: 877.4711. Found: 877.4706.

Synthesis of Aldehydes 15–22. General Procedure

Compound **10** (0.95 mmol) was dissolved in anhydrous dichloromethane (30 mL) under a nitrogen atmosphere and cooled to 0 °C. Dess–Martin periodinane reagent (1.21 g, 2.85 mmol, 3.0 equiv) was added to the reaction mixture with stirring. The ice bath was removed, and the reaction mixture was stirred at room temperature for 3 h (monitoring by TLC indicated complete disappearance of the starting material). A solution of 40 mM sodium thiosulfate in saturated aqueous NaHCO₃ (50 mL) was added, and the solution was stirred for another 15 min. The aqueous layer was removed, and the organic layer was washed with sodium bicarbonate (25 mL), water (2 × 25 mL), and brine (25 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The yellow residue was purified by flash chromatography (silica gel/methylene chloride/ethyl acetate/methanol) to yield aldehydes **15–22**.

tert-Butyl ((7S,10S,13S)-7-Formyl-10-isobutyl-4,9,12-trioxo-3,8,11-triaza-1(2,5)-oxadiazolacyclotetradecaphane-13-yl)-carbamate (15)

Yield (43%), mp 91–94 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.84–0.97 (m, 6 H), 1.17–1.30 (m, 1 H), 1.38–1.50 (s, 9 H), 1.63–1.71 (m, 2 H), 2.37–2.48 (m, 2 H), 2.54–2.63 (m, 2 H), 2.90–2.97 (m, 1 H), 3.12–3.19 (m, 1 H), 4.35–4.43 (m, 2 H), 4.50–4.61 (s, 2 H), 4.65–4.70 (m, 1 H), 6.94–7.01 (d, 1 H), 7.18–7.23 (d, 1 H), 7.79–7.91 (d, 1 H), 8.14–8.19 (d, 1 H), 9.55–9.60 (s, 1 H). HRMS (ESI) calcd for C₂₂H₃₅N₆O₇, [M + H]⁺: 495.2567. Found: 495.2887.

tert-Butyl ((7S,10S,13S)-7-Formyl-10-isobutyl-4,9,12-trioxo-3,8,11-triaza-1(2,5)-oxadiazolacyclopentadecaphane-13-yl)-carbamate (16)

Yield (40%), mp 99–102 °C. ¹H NMR (400 MHz, CDCl₃) δ 0.84–0.97 (m, 6 H), 1.17–1.30 (m, 1 H), 1.38–1.50 (s, 9 H), 1.63–1.71 (m, 3 H), 2.37–2.48 (m, 3 H), 2.54–2.63 (m, 2 H),

2.88–2.97 (m, 2 H), 4.35–4.43 (m, 3 H), 4.45–4.56 (s, 2 H), 6.94–7.01 (d, 1 H), 7.18–7.23 (d, 1 H), 7.79–7.91 (d, 1 H), 8.14–8.19 (d, 1 H), 9.55–9.60 (s, 1 H). HRMS (ESI) calcd for $C_{23}H_{36}N_6O_7Na$, $[M + Na]^+$: 531.2543. Found: 531.2520.

***tert*-Butyl ((8S,11S,14S)-8-Formyl-11-isobutyl-5,10,13-trioxo-4,9,12-triaza-1(2,5)-oxadiazolacyclohexadecaphane-14-yl)-carbamate (17)**

Yield (45%), mp 76–78 °C. 1H NMR (400 MHz, $CDCl_3$) δ 0.83–0.95 (d, 6 H), 1.11–1.23 (m, 1 H), 1.26 (br s, 2 H), 1.43–1.46 (s, 9 H), 1.56–1.69 (m, 3 H), 2.37–2.50 (m, 2 H), 2.89–3.00 (m, 3 H), 3.01–3.05 (m, 1 H), 3.42–3.54 (m, 1 H), 3.57–3.69 (m, 2 H), 4.47–4.52 (m, 3 H), 7.26–7.30 (m, 1 H), 7.09–7.13 (d, 1 H), 7.63–7.72 (d, 1 H), 7.90–8.02 (d, 1 H), 9.50–9.52 (s, 1 H). HRMS (ESI) calcd for $C_{24}H_{38}N_6O_6$, $[M + H]^+$: 523.28. Found: 523.3.

***tert*-Butyl ((8S,11S,14S)-11-(Cyclohexylmethyl)-8-formyl-5,10,13-trioxo-4,9,12-triaza-1(2,5)-oxadiazolacyclohexa-decaphane-14-yl)carbamate (18)**

Yield (50%), mp 106–108 °C. 1H NMR (400 MHz, $CDCl_3$) δ 0.84–0.96 (m, 4 H), 1.11–1.21 (m, 4 H), 1.44–1.48 (s, 9 H), 1.59–1.71 (m, 2 H), 2.00–2.13 (m, 2 H), 2.15–2.27 (m, 2 H), 2.38–2.49 (m, 2 H), 2.85–2.97 (m, 2 H), 3.55–3.67 (m, 5 H), 3.92–4.02 (m, 2 H), 4.37–4.46 (m, 3 H), 7.26–7.38 (m, 1 H), 7.67–7.80 (d, 1 H), 7.86–7.97 (d, 1 H), 8.20–8.23 (d, 1 H), 9.49–9.51 (s, 1 H). HRMS (ESI) calcd for $C_{27}H_{42}N_6O_6Na$, $[M + Na]^+$: 585.3013. Found: 585.3002.

***tert*-Butyl ((9S,12S,15S)-9-Formyl-12-isobutyl-6,11,14-trioxo-5,10,13-triaza-1(2,5)-oxadiazolacycloheptadecaphane-15-yl)-carbamate (19)**

Yield (45%), mp 86–88 °C. 1H NMR (400 MHz, $CDCl_3$) δ 0.84–0.97 (m, 6 H), 1.17–1.30 (m, 1 H), 1.38–1.50 (s, 9 H), 1.63–1.71 (m, 3 H), 1.97–2.09 (m, 4 H), 2.37–2.48 (m, 2 H), 2.54–2.63 (m, 2 H), 2.88–2.97 (m, 1 H), 3.63–3.71 (m, 1 H), 3.73–3.85 (m, 2 H), 4.19–4.30 (m, 1 H), 4.35–4.43 (m, 1 H), 4.45–4.56 (m, 2 H), 6.97–7.06 (d, 1 H), 7.10–7.18 (d, 1 H), 7.99–8.05 (d, 1 H), 8.24–8.33 (d, 1 H), 9.52–9.60 (s, 1 H). HRMS (ESI) calcd for $C_{27}H_{38}N_6O_7Na$, $[M + Na]^+$: 545.2700. Found: 545.2613.

***tert*-Butyl ((9S,12S,15S)-12-(Cyclohexylmethyl)-9-formyl-6,11,14-trioxo-5,10,13-triaza-1(2,5)-oxadiazolacyclohepta-decaphane-15-yl)carbamate (20)**

Yield (45%), mp 96–99 °C. 1H NMR (400 MHz, $CDCl_3$) δ 0.85–0.98 (m, 4 H), 1.10–1.22 (m, 6 H), 1.43–1.46 (s, 9 H), 1.60–1.72 (m, 3 H), 1.90–1.96 (m, 2 H), 1.98–2.08 (m, 4 H), 2.31–2.43 (m, 2 H), 2.86–2.98 (m, 4 H), 3.44–3.51 (m, 1 H), 3.85 (td, $J = 5.97, 3.59$ Hz, 2 H), 3.90–4.02 (m, 1 H), 4.27–4.39 (m, 2 H), 4.49 (br s, 1 H), 5.94–6.07 (d, 1 H), 6.87–6.98 (br s, 1 H), 7.87–7.92 (d, 1 H), 8.00–8.05 (d, 1 H), 9.48–9.59 (d, 1 H). HRMS (ESI) calcd for $C_{28}H_{45}N_6O_7$, $[M + H]^+$: 577.3350. Found: 577.3145.

***tert*-Butyl ((4S,7S,10S)-7-(Cyclohexylmethyl)-10-formyl-5,8,13-trioxo-6,9,14-triaza-1(2,5)-oxadiazolacycloocta-decaphane-4-yl)carbamate (21)**

Yield (52%), mp 80–83 °C. 1H NMR (400 MHz, $CDCl_3$) δ 0.85–0.98 (m, 4 H), 1.10–1.22 (m, 6 H), 1.43–1.46 (s, 9 H), 1.60–1.72 (m, 3 H), 1.90–1.96 (m, 2 H), 1.98–2.08 (m, 4 H), 2.31–2.43 (m, 2 H), 2.86–2.98 (m, 4 H), 3.44–3.51 (m, 1 H), 3.85 (td, $J = 5.97, 3.59$ Hz, 2

H), 3.90–4.02 (m, 1 H), 4.27–4.39 (m, 2 H), 4.49 (br s, 1 H), 7.02–7.10 (d, 1 H), 7.31–7.40 (br s, 1 H), 7.77–7.81 (d, 1 H), 8.01–8.05 (d, 1 H), 9.48–9.59 (d, 1 H). HRMS (ESI) calcd for $C_{29}H_{46}N_6O_7Na$, $[M + Na]^+$: 613.3326. Found: 613.3299.

***tert*-Butyl ((4*S*,7*S*,10*S*)-7-(Cyclohexylmethyl)-10-formyl-5,8,13-trioxo-6,9,14-triaza-1(2,5)-oxadiazolacyclonona-decaphane-4-yl)carbamate (**22**)**

Yield (50%), mp 106–109 °C. 1H NMR (400 MHz, $CDCl_3$) δ 0.87–0.99 (m, 4 H), 1.14–1.23 (m, 4 H), 1.34–1.37 (m, 1 H), 1.44–1.54 (s, 9 H), 1.63–1.75 (m, 8 H), 2.01–2.12 (m, 2 H), 2.12–2.24 (m, 4 H), 2.30 (br s, 2 H), 2.87–2.97 (m, 2 H), 3.43–3.55 (m, 4 H), 4.37–4.49 (m, 3 H), 6.74–6.84 (m, 1 H), 7.11–7.23 (m, 1 H), 7.46–7.54 (d, 1 H), 7.98–8.06 (m, 1 H), 9.50–9.55 (s, 1 H). HRMS (ESI) calcd for $C_{30}H_{48}N_6O_7Na$, $[M + Na]^+$: 627.3482. Found: 627.3465.

Enzyme Assays and Inhibition Studies

These studies were carried out as described previously.^{26,28,41} The NV 3CLpro fluorescence resonance energy transfer (FRET) assay was performed using a fluorogenic substrate (Edans-DFHLQGP-DabcyI) which is derived from the cleavage sites on NV polypeptides. Methods for FRET assay and determination of the IC_{50} values of protease inhibitors against 3CLpro were described previously by our lab.^{26,28,41}

Antiviral Assays

Each compound was evaluated for anti-3CLpro effects up to 100 μM . For the cell based assay, 1 day old HG23 cells (NV replicon harboring cells) were treated with various concentrations (1.0–100 μM) of each compound and incubated for 48 h. Then total RNA was extracted from cells for qRT-PCR for norovirus and β -actin. The EC_{50} and EC_{90} (the 50% and 90% inhibitory concentration in cell based assay, respectively) of each compound were calculated by the % reduction of RNA levels to Mock-treated cells after normalization with β -actin levels. Each compound was also tested against MNV-1. Confluent RAW267.4 was inoculated with MNV-1 at a MOI of 0.05, and at the same time, various concentrations (1.0–100 μM) of each compound were added to the medium. Virus infected cells were further incubated for 72 h until extensive cytopathic effects (CPE) progress. The EC_{50} of each compound was determined by 50% inhibition of CPE progress (cell death) by each compound at 48 h using a CytoTox96 nonradioactive cytotoxicity assay kit (Promega, Madison, WI) following the manufacturer's instructions. Cell cytotoxicity for each compound in HG23 cells was also measured by the cytotoxicity assay kit with serial dilution up to 100 μM . The CC_{50} (the 50% cytotoxic concentration) was determined for each compound. The IC_{50} , EC_{50} , or CC_{50} values were determined by at least two independent experiments.

X-ray Crystallographic Studies. Crystallization and Data Collection

Purified norovirus 3CL protease (3CLpro) in 100 mM NaCl, 50 mM PBS, pH 7.2, 1 mM DTT at a concentration of 10 mg/mL was used for the preparation of the enzyme: **22** complex. Stock solutions of 100 mM **21** and **22** were prepared in DMSO and the 3CLpro:inhibitor complex was prepared by mixing 7 μL of the inhibitors (3 mM) with 243

μL (0.49 mM) of 3CLpro and incubating on ice for 1 h. The buffer was exchanged to 100 mM NaCl, 20 mM Tris, pH 8.0, using a Zeba spin desalting column (MWCO = 7 kDa, Life Technologies), and the sample was concentrated to 10.0 mg/mL for crystallization screening. All crystallization experiments were conducted using a Compact Jr. (Rigaku Reagents) sitting drop vapor diffusion plates at 20 °C and equal volumes of protein and crystallization solution equilibrated against 75 μL of the latter. Crystals were obtained from the from the Index HT screen (Hampton Research). Prismatic crystals of NV 3CLpro:**21** were obtained in 2 days from condition E9 (30% v/v pentaerythritol ethoxylate (15/4 EO/OH), 50 mM Bis-Tris, pH 6.5, 50 mM ammonium sulfate). Crystals of NV 3CLpro:**22** displaying a needle morphology were obtained in 2–3 days condition H12 (30% (w/v) PEG 2000 MME, 150 mM potassium bromide). Samples were cryoprotected in a fresh drop crystallant for NV 3CLpro:**21** and 80% crystallization solution/20% glycerol for NV 3CLpro:**22**, before storing in liquid nitrogen. X-ray diffraction data were collected at the Advanced Photon Source beamline 17-ID using a Dectris Pilatus 6M pixel array detector.

Structure Solution and Refinement

Intensities were integrated using XDS,^{44,45} and the Laue class analysis and data scaling were performed with Aimless⁴⁶ which suggested that the highest probability Laue class was $2/m$ ($C2$) for NV 3CLpro:**21** and mmm ($P2_12_12_1$) for NV 3CLpro:**22**. Structure solution was conducted by molecular replacement with Phaser⁴⁷ using a previously determined isomorphous structure of inhibitor bound norovirus 3CLpro (PDB code 3UR9) as the search model. Structure refinement and manual model building were conducted with Phenix⁴⁸ and Coot,⁴⁹ respectively. Disordered side chains were truncated to the point for which electron density could be observed. All atoms were refined with anisotropic atomic displacement parameters for NV 3CLpro:**21**. Structure validation was conducted with Molprobit,⁵⁰ and figures were prepared using the CCP4MG package.⁵¹ Coordinates and structure factors were deposited to the wwPDB with the accession codes 5DGJ (NV 3CLpro:**21**) and 5DG6 (NV 3CLpro:**22**).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The generous financial support of this work by the National Institutes of Health (Grant R01 AI109039) is gratefully acknowledged. Use of the University of Kansas Protein Structure Laboratory was supported by grants from the National Center for Research Resources (Grant 5P20RR017708-10) and the National Institute of General Medical Sciences (Grant 8P20GM103420-10). Use of the IMCA-CAT beamline 17-ID at the Advanced Photon Source was supported by the companies of the Industrial Macro-molecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract DE-AC02-06CH11357.

ABBREVIATIONS USED

ORF	open reading frame
EDCI	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide

HOBt	<i>N</i> -hydroxybenzo-triazole
DIEA	diisopropylethylamine
DTT	dithiothreitol
DMSO	dimethyl sulfoxide
MNV	murine norovirus
MOI	multiplicity of infection
CPE	cytopathic effect
TCID₅₀	the 50% tissue culture infectious dose
IC₅₀	the 50% inhibitory concentration in the enzyme assay
EC₅₀	the 50% effective concentration in cell culture
CC₅₀	50% cytotoxic concentration in cell-based assays
GESAMT	general efficient structural alignment of macromolecular targets
rmsd	root-mean-square deviation
XDS	X-ray detector software
MME	monomethyl ether

References

- Green, KY. Caliciviridae: The Noroviruses. In: Knipe, DM.; Howley, PM., editors. *Green's Virology*. Vol. 1. Lippincott Williams & Wilkins; Philadelphia, PA: 2007. p. 949-979.
- Koo HL, Ajami N, Atmar RL, DuPont HL. Noroviruses: The Leading Cause of Gastroenteritis Worldwide. *Discovery Med*. 2010; 10:61–70.
- Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, Koopmans M, Lopman BA. Global Prevalence of Norovirus in Cases of Gastroenteritis: a Systematic Review and Meta-Analysis. *Lancet Infect Dis*. 2014; 14:725–730. [PubMed: 24981041]
- Hall AJ, Lopman BA, Payne DC, Patel MM, Gastanaduy PA, Vinje J, Parashar UD. Norovirus Disease in the United States. *Emerging Infect Dis*. 2013; 19:1198–1205. [PubMed: 23876403]
- [accessed January 2015] Norovirus. www.cdc.gov/norovirus
- Bok K, Green KY. Norovirus Gastroenteritis in Immunocompromised Patients. *N Engl J Med*. 2012; 367:2126–2132. [PubMed: 23190223]
- Robilotti E, Deresinski S, Pinsky BA. Norovirus. *Clin Microbiol Rev*. 2015; 28:134–164. [PubMed: 25567225]
- Lee BE, Pang XL. New Strains of Norovirus and the Mystery of Viral Gastroenteritis Epidemics. *CMAJ*. 2013; 185:1381–1382. [PubMed: 24003105]
- Hall AJ. Noroviruses: The Perfect Human Pathogens? *J Infect Dis*. 2012; 205:1622–1624. [PubMed: 22573872]
- Pringle K, Lopman B, Vega E, Vinje J, Parashar UD, Hall AJ. Noroviruses: Epidemiology, Immunity and Prospects for Prevention. *Future Microbiol*. 2015; 10:53–67. [PubMed: 25598337]
- Jones MK, Grau KR, Costantini V, Kolawole AO, de Graaf M, Freiden P, Graves CL, Koopmans M, Walleet SM, Tibbetts SA, Schultz-Cherry S, Wobus CE, Vinje J, Karst SM. Human Norovirus Culture in B Cells. *Nat Protoc*. 2015; 10:1939–1947. [PubMed: 26513671]

12. Karst SM, Zhu S, Goodfellow IG. The Molecular Pathology of Noroviruses. *J Pathol.* 2015; 235:206–216. [PubMed: 25312350]
13. Thorne LG, Goodfellow IG. Norovirus Gene Expression and Replication. *J Gen Virol.* 2014; 95:278–291. [PubMed: 24243731]
14. Blakeney SJ, Cahill A, Reilly PA. Processing of Norwalk Virus Nonstructural Proteins by a 3C-like Cysteine Proteinase. *Virology.* 2003; 308:216–224. [PubMed: 12706072]
15. Hussey RJ, Coates L, Gill RS, Erskine PT, Coker SF, Mitchell E, Cooper JB, Wood S, Broadbridge R, Clarke IN, Lambden PR, Shoolingin-Jordan PM. A Structural Study of Norovirus 3C Protease Specificity: Binding of a Designed Active Site-Directed Peptide Inhibitor. *Biochemistry.* 2011; 50:240–249. [PubMed: 21128685]
16. Herod MR, Prince CA, Skilton RJ, Ward VK, Cooper JB, Clarke IN. Structure-based Design and Functional Studies of Novel Noroviral 3C Protease Chimaeras Offer Insights into Substrate Specificity. *Biochem J.* 2014; 464:461–472. [PubMed: 25275273]
17. Nomenclature used is that of the following: Schechter I, Berger A. *Biochem Biophys Res Commun.* 1967; 27:157–162. [PubMed: 6035483] where $S_1, S_2, S_3, \dots, S_n$ and $S'_1, S'_2, S'_3, \dots, S'_n$ correspond to the enzyme subsites on the N-terminus and C-terminus side, respectively, of the scissile bond. Each subsite accommodates a corresponding amino acid residue side chain designated $P_1, P_2, P_3, \dots, P_n$ and $P'_1, P'_2, P'_3, \dots, P'_n$ of a substrate or inhibitor. S_1 is the primary substrate specificity subsite and $P_1-P'_1$ is the scissile bond..
18. Muhaxhiri Z, Deng L, Shanker S, Sankaran B, Estes MK, Palzkill T, Song Y, Venkataraman Prasad BV. Structural Basis of Substrate Specificity and Protease Inhibition in Norwalk Virus. *J Virol.* 2013; 87:4281–4292. [PubMed: 23365454]
19. Hardy ME, Crone TJ, Brower JE, Ettayebi K. Substrate Specificity of the Norwalk Virus 3C-Like Proteinase. *Virus Res.* 2002; 89:29–39. [PubMed: 12367748]
20. Someya Y, Takeda N, Miyamura T. Characterization of the Norovirus 3C-like Protease. *Virus Res.* 2005; 110:91–97. [PubMed: 15845259]
21. Mullard A. 2013 FDA Drug Approvals. *Nat Rev Drug Discovery.* 2014; 13:85–89. [PubMed: 24481294]
22. Drag M, Salvesen GS. Emerging Principles in Protease-Based Drug Discovery. *Nat Rev Drug Discovery.* 2010; 9:690–701. [PubMed: 20811381]
23. Tiew KC, He G, Aravapalli S, Mandadapu SR, Gunnam MR, Alliston KR, Lushington GH, Kim Y, Chang KO, Groutas WC. Design, Synthesis, and Evaluation of Inhibitors of Norwalk Virus 3C Protease. *Bioorg Med Chem Lett.* 2011; 21:5315–5319. [PubMed: 21802286]
24. Mandadapu SR, Weerawarna PM, Gunnam MR, Alliston KR, Lushington GH, Kim Y, Chang KO, Groutas WC. Potent Inhibition of Norovirus 3CL Protease by Peptidyl α -Ketoamides and α -Keto heterocycles. *Bioorg Med Chem Lett.* 2012; 22:4820–4826. [PubMed: 22698498]
25. Mandadapu SR, Gunnam MR, Galasiti Kankanamalage AC, Uy RAZ, Alliston KR, Lushington GH, Kim Y, Chang KO, Groutas WC. Potent Inhibition of Norovirus by Dipeptidyl α -Hydroxyphosphonate Transition State Mimics. *Bioorg Med Chem Lett.* 2013; 23:5941–5944. [PubMed: 24054123]
26. Kim Y, Lovell S, Tiew KC, Mandadapu SR, Alliston KR, Battaile KP, Groutas WC, Chang KO. Broad-Spectrum Antivirals Against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses. *J Virol.* 2012; 86:11754–11762. [PubMed: 22915796]
27. Mandadapu SR, Weerawarna PM, Prior AM, Uy RAZ, Aravapalli S, Alliston KR, Lushington GH, Kim Y, Hua DH, Chang KO, Groutas WC. Macrocyclic Inhibitors of 3C and 3C-like Proteases of Picornavirus, Norovirus and Coronavirus. *Bioorg Med Chem Lett.* 2013; 23:3709–3712. [PubMed: 23727045]
28. Galasiti Kankanamalage AC, Kim Y, Weerawarna PM, Uy RAZ, Damalanka VC, Mandadapu SR, Alliston KR, Mehzaheen N, Battaile KP, Lovell S, Chang KO, Groutas WC. Structure-Guided Design and Optimization of Dipeptidyl Inhibitors of Norovirus 3CL Protease. Structure-Activity Relationships and Biochemical, X-Ray crystallographic, Cell-based and In Vivo Studies. *J Med Chem.* 2015; 58:3144–3155. [PubMed: 25761614]
29. Lin JH. Pharmacokinetics of Biotech Drugs: Peptides, Proteins, and Monoclonal Antibodies. *Curr Drug Metab.* 2009; 10:661–691. [PubMed: 19702530]

30. Craik DJ, Fairlie DP, Liras S, Price D. The Future of Peptide-Based Drugs. *Chem Biol Drug Des.* 2013; 81:136–147. [PubMed: 23253135]
31. Mallinson J, Collins I. Macrocyces in New Drug Discovery. *Future Med Chem.* 2012; 4:1409–1438. [PubMed: 22857532]
32. Marsault E, Peterson ML. Macrocyces are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocyces in Drug Discovery. *J Med Chem.* 2011; 54:1961–2004. [PubMed: 21381769]
33. Giordanetto F, Kihlberg J. Macrocytic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their properties? *J Med Chem.* 2014; 57:278–295. [PubMed: 24044773]
34. Mathiowetz, AM.; Leung, SSF.; Jacobson, MP. Optimizing the Permeability and Oral Bioavailability of Macrocyces. In: Levin, J., editor. *Macrocyces in Drug Discovery.* Royal Society of Chemistry; Cambridge, U.K: 2015. p. 367-397.
35. Alex A, Millan DS, Perez M, Wakenhut F, Whitlock GA. Intramolecular Hydrogen Bonding to Improve Membrane Permeability and Absorption in Beyond the Rule of Five Chemical Space. *Med Chem Comm.* 2011; 2:669–674.
36. Rezaei T, Yu B, Millhauser GL, Jacobson MP, Lokey RS. Testing the Conformational Hypothesis of Passive Membrane Permeability Using Synthetic Cyclic Peptide Diastereomers. *J Am Chem Soc.* 2006; 128:2510–2511. [PubMed: 16492015]
37. Tyndall JDA, Fairlie DP. Macrocyces Mimic The Extended Peptide Conformation Recognized By Aspartic, Serine, Cysteine and Metallo Proteases. *Curr Med Chem.* 2001; 8:893–907. [PubMed: 11375757]
38. (a) Tyndall JD, Nall T, Fairlie DP. Proteases Universally Recognize β -Strands in Their Active Sites. *Chem Rev.* 2005; 105:973–999. [PubMed: 15755082] (b) Madala PK, Tyndall JD, Nall T, Fairlie DP. Update 1 of Proteases Universally Recognize β -Strands in Their Active Sites. *Chem Rev.* 2010; 110:PR1–PR31.
39. Stabile P, Lamonica A, Ribecai A, Castoldi D, Guercio G, Curcuruto O. Mild and Convenient One-pot Synthesis of 1,3,4-Oxadiazoles. *Tetrahedron Lett.* 2010; 51:4801–4805.
40. Xue CB, He X, Roderick J, DeGrado WF, Cherney RJ, Hardman KD, Nelson DJ, Copeland RA, Jaffee BD, Decicco CP. Design and Synthesis of Cyclic Inhibitors of Matrix Metalloproteinases and TNF- α Production. *J Med Chem.* 1998; 41:1745–1748. [PubMed: 9599225]
41. Chang KO, Takahashi T, Prakash O, Kim Y. Characterization and Inhibition of Norovirus Proteases of Genogroups I and II Using a Fluorescence Resonance Energy Transfer Assay. *Virology.* 2012; 423:125–133. [PubMed: 22200497]
42. Takahashi D, Hiromasa Y, Kim Y, Anbanandam A, Yao X, Chang K, Prakash O. Structural and Dynamics Characterization of Norovirus Protease. *Protein Sci.* 2013; 22:347–357. [PubMed: 23319456]
43. Krissinel E. Enhanced Fold Recognition Using Efficient Short Fragment Clustering. *J Mol Biochem.* 2012; 1:76–85. [PubMed: 27882309]
44. Kabsch W. Automatic Indexing of Rotation Diffraction Patterns. *J Appl Crystallogr.* 1988; 21:67–72.
45. Kabsch W. *Acta Crystallogr, Sect D: Biol Crystallogr.* 2010; 66:125–132. [PubMed: 20124692]
46. Evans PR. An Introduction to Data Reduction: Space-group Determination, Scaling and Intensity Statistics. *Acta Crystallogr, Sect D: Biol Crystallogr.* 2011; 67:282–292. [PubMed: 21460446]
47. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn M, Storoni LC, Read RJ. Phaser Crystallographic Software. *J Appl Crystallogr.* 2007; 40:658–674. [PubMed: 19461840]
48. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. PHENIX: a Comprehensive Python-based System for Macromolecular Structure Solution. *Acta Crystallogr, Sect D: Biol Crystallogr.* 2010; 66:213–221. [PubMed: 20124702]
49. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and Development of Coot. *Acta Crystallogr, Sect D: Biol Crystallogr.* 2010; 66:486–501. [PubMed: 20383002]

50. Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: All-atom Structure Validation for Macromolecular Crystallography. *Acta Crystallogr, Sect D: Biol Crystallogr.* 2010; 66:12–21. [PubMed: 20057044]
51. Potterton L, McNicholas S, Krissinel E, Gruber J, Cowtan K, Emsley P, Murshudov GN, Cohen S, Perrakis A, Noble M. Developments in the CCP4 Molecular Graphics Project. *Acta Crystallogr, Sect D: Biol Crystallogr.* 2004; 60:2288–2294. [PubMed: 15572783]
52. Evans P. Scaling and Assessment of Data Quality. *Acta Crystallogr, Sect D: Biol Crystallogr.* 2006; 62:72–82. [PubMed: 16369096]
53. Diederichs K, Karplus PA. Improved R-factors for Diffraction Data Analysis in Macromolecular Crystallography. *Nat Struct Biol.* 1997; 4:269–275. [PubMed: 9095194]
54. Weiss MS. Global Indicators of X-ray Data Quality. *J Appl Crystallogr.* 2001; 34:130–135.
55. Karplus PA, Diederichs K. Linking Crystallographic Model and Data Quality. *Science.* 2012; 336:1030–1033. [PubMed: 22628654]
56. Evans P. Biochemistry. Resolving Some Old Problems in Protein Crystallography. *Science.* 2012; 336:986–987. [PubMed: 22628641]




Figure 2. Dose-dependent inhibition of NV RNA levels by compound **21**. Various concentrations of compound **21** (0.1–40 μM) were incubated in NV replicon cells for 48 h, and NV RNA levels were measured by quantitative real-time RT-PCR.




Figure 3.
 $F_o - F_c$ map (green mesh) contoured at 3σ and $2F_o - F_c$ map (blue mesh) contoured at 1σ for of macrocyclic inhibitors (A) **22** and (B) **21** covalently bound to the catalytic cysteine residue (Cys139) of NV 3CLpro.




Figure 4. Surface representation of inhibitor **22** bound to NV 3CLpro with neighboring residues colored yellow (nonpolar), cyan (polar), and white (weakly polar). The P2 cyclohexylalanine side chain is snugly nestled into the hydrophobic S₂ subsite.




Figure 5.
Hydrogen bonding interactions represented as dashed lines between NV 3CLpro and inhibitors (A) **22** and (B) **21**.








Figure 6. Superposition of NV 3CLpro complexes with inhibitors **21** (green) and **22** (magenta). The disordered portion in inhibitor **21** was modeled in an idealized geometry for comparison with inhibitor **22**.

**Scheme 1a.**

^a(a) *tert*-Butyl carbazate, EDCI; (b) HCl, dioxane, DCM; (c) (L)Boc-L-Glu-OMe, EDCI, HOBt, DIEA, DMF; (d) TsCl, DIEA; (e) LiOH, H₂O, THF; (f) NaHCO₃, CH₃I, DMF; (g) HCl, dioxane; (h) Boc-L-Leu-OH, EDCI, HOBt, DIEA, DMF.

**Scheme 2a.**

^a(a) EDCl, HOBT, DIEA, DMF; (b) H₂, Pd-C; (c) LiBH₄, THF; (d) Dess–Martin periodinane, DCM.

**Scheme 3a.**

^a(a) EDCl, HOBT, DIEA, DMF; (b) 1 M LiOH, H₂O, THF.

Table 1

Activity of Compounds 15–22 against NV 3CL Protease and Norovirus in the Cell-Based Replicon System^a

compd	R	n	m	ring size	NV 3CLpro, IC ₅₀ (μM)	NV (replicon cells)			CC ₅₀ (μM)
						EC ₅₀ (μM)	EC ₉₀ (μM)	MNV, EC ₅₀ (μM)	
15	Leu	1	1	16	>100	19.4 ± 10.8	>100	>100	>100
16	Leu	1	2	17	34.3 ± 6.9	18.1 ± 8.3	72.7 ± 5.6	>100	>100
17	Leu	2	2	18	15.3 ± 4.5	2.5 ± 1.5	23.4 ± 8.5	9.8 ± 3.3	>100
18	Cha	2	2	18	14.5 ± 3.8	5.1 ± 2.9	38.2 ± 5.2	19.9 ± 2.2	>100
19	Leu	2	3	19	21.3 ± 4.3	5.9 ± 4.5	30.5 ± 3.1	11.1 ± 3.6	>100
20	Cha	2	3	19	45.1 ± 4.6	9.4 ± 5.7	73.3 ± 4.5	>100	>100
21	Cha	2	4	20	18.5 ± 5.7	6.5 ± 2.7	18.2 ± 2.1	10.9 ± 2.3	>100
22	Cha	2	5	21	8.6 ± 3.7	51.2 ± 19.8	>100	>100	>100

^a3CLpro, 3CL protease; IC₅₀, 50% inhibitory concentration determined by the enzyme assay; EC₅₀ and EC₉₀, 50% or 90% effective concentration determined by cell-based assays, respectively; CC₅₀, 50% cytotoxic concentration in cell-based assays. Mean and the standard deviation of the mean are shown for EC₅₀ and EC₉₀ values.

Table 2

Crystallographic Data for NV 3CLpro:21 and NV 3CLpro:22 Complexes

	NV 3CLpro:21	NV 3CLpro:22
Data Collection		
unit-cell parameter	$a = 65.17 \text{ \AA}, b = 41.18 \text{ \AA}, c = 61.68 \text{ \AA}, \beta = 109.4^\circ$	$a = 37.69 \text{ \AA}, b = 67.11 \text{ \AA}, c = 127.47 \text{ \AA}$
space group	$C2$	$P2_12_12_1$
resolution (\AA) ^a	34.21–1.00 (1.02–1.00)	42.49–2.35 (2.43–2.35)
wavelength (\AA)	1.0000	1.0000
temp (K)	100	100
observed reflections	261 523	91 527
unique reflections	82 788	14 146
$\langle I/\sigma(I) \rangle$ ^a	12.1 (1.9)	9.9 (2.1)
completeness (%) ^a	99.5 (90.7)	100 (100)
multiplicity ^a	3.2 (2.2)	6.5 (6.4)
R_{merge} (%) ^{a,a}	4.7 (47.4)	15.1 (86.8)
R_{meas} (%) ^{a,d}	5.6 (60.3)	16.4 (94.5)
R_{pim} (%) ^{a,e}	3.0 (36.7)	6.4 (36.9)
$CC_{1/2}$ ^{a,e}	0.994 (0.764)	0.995 (0.798)
Refinement		
resolution (\AA) ^a	32.20–1.00	35.90–2.35
reflections (working/test) ^a	78 788/3 986	13 379/712
$R_{\text{factor}}/R_{\text{free}}$ (%) ^{a,c}	14.3/15.4	20.9/27.8
no. of atoms (protein/ligand/water)	1319/34/132	2336/43/55
Model Quality		
rms deviation		
bond length (\AA)	0.007	0.007
bond angle (deg)	1.033	0.918
average B -factor (\AA^2)		
all atoms	16.9	34.5
protein	15.4	34.6
ligand	21.0	35.8
water	31.0	30.8
coordinate error (max likelihood) (\AA)	0.07	0.31
Ramachandran plot		
most favored (%)	98.9	93.9
additionally allowed (%)	1.1	5.2

^aValues in parentheses are for the highest resolution shell.

^b $R_{\text{merge}} = \sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle| / \sum_{hkl} \sum_i I_i(hkl)$, where $I_i(hkl)$ is the intensity measured for the i th reflection and $\langle I(hkl) \rangle$ is the average intensity of all reflections with indices hkl .

^c $R_{\text{factor}} = \frac{\sum_{hkl} |F_{\text{obs}}(hkl) - |F_{\text{calc}}(hkl)||}{\sum_{hkl} F_{\text{obs}}(hkl)}$; R_{free} is calculated in an identical manner using 5% of randomly selected reflections that were not included in the refinement.

^d R_{meas} = redundancy-independent (multiplicity-weighted) R_{merge} .⁵² R_{pim} = precision-indicating (multiplicity-weighted) R_{merge} .^{53,54}

^e $CC_{1/2}$ is the correlation coefficient of the mean intensities between two random half-sets of data.^{55,56}

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript